


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T14:04:00Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406090" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406090</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" id="liv70314" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Liver Int</journal-id><journal-id journal-id-type="iso-abbrev">Liver Int</journal-id><journal-id journal-id-type="pmc-domain-id">379</journal-id><journal-id journal-id-type="pmc-domain">blackwellopen</journal-id><journal-id journal-id-type="publisher-id">LIV</journal-id><journal-title-group><journal-title>Liver International</journal-title></journal-title-group><issn pub-type="ppub">1478-3223</issn><issn pub-type="epub">1478-3231</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Wiley Open Access Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406090</article-id><article-id pub-id-type="pmcid-ver">PMC12406090.1</article-id><article-id pub-id-type="pmcaid">12406090</article-id><article-id pub-id-type="pmcaiid">12406090</article-id><article-id pub-id-type="pmid">40899194</article-id><article-id pub-id-type="doi">10.1111/liv.70314</article-id><article-id pub-id-type="publisher-id">LIV70314</article-id><article-id pub-id-type="other">LIVint-24-02561</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Smoking Aggravates Inflammation, Fibrogenesis, Angiogenesis and Cancer Risk in Patients With Cirrhosis</article-title></title-group><contrib-group><contrib id="liv70314-cr-0001" contrib-type="author"><name name-style="western"><surname>Dominik</surname><given-names initials="N">Nina</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0009-4615-915X</contrib-id><xref rid="liv70314-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="liv70314-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="liv70314-cr-0002" contrib-type="author"><name name-style="western"><surname>Simbrunner</surname><given-names initials="B">Benedikt</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8181-9146</contrib-id><xref rid="liv70314-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="liv70314-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="liv70314-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="liv70314-cr-0003" contrib-type="author"><name name-style="western"><surname>Scheiner</surname><given-names initials="B">Bernhard</given-names></name><xref rid="liv70314-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="liv70314-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="liv70314-cr-0004" contrib-type="author"><name name-style="western"><surname>Schwarz</surname><given-names initials="M">Michael</given-names></name><xref rid="liv70314-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="liv70314-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="liv70314-cr-0005" contrib-type="author"><name name-style="western"><surname>Hartl</surname><given-names initials="L">Lukas</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3398-6120</contrib-id><xref rid="liv70314-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="liv70314-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="liv70314-cr-0006" contrib-type="author"><name name-style="western"><surname>Jachs</surname><given-names initials="M">Mathias</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2871-4147</contrib-id><xref rid="liv70314-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="liv70314-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="liv70314-cr-0007" contrib-type="author"><name name-style="western"><surname>Balcar</surname><given-names initials="L">Lorenz</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6708-3061</contrib-id><xref rid="liv70314-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="liv70314-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="liv70314-cr-0008" contrib-type="author"><name name-style="western"><surname>Semmler</surname><given-names initials="G">Georg</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0411-166X</contrib-id><xref rid="liv70314-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="liv70314-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="liv70314-cr-0009" contrib-type="author"><name name-style="western"><surname>Kramer</surname><given-names initials="G">Georg</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0008-1736-3699</contrib-id><xref rid="liv70314-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="liv70314-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="liv70314-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="liv70314-cr-0010" contrib-type="author"><name name-style="western"><surname>Sebesta</surname><given-names initials="C">Christian</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0001-7504-8506</contrib-id><xref rid="liv70314-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="liv70314-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="liv70314-cr-0011" contrib-type="author"><name name-style="western"><surname>Trauner</surname><given-names initials="M">Michael</given-names></name><xref rid="liv70314-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="liv70314-cr-0012" contrib-type="author"><name name-style="western"><surname>Pinter</surname><given-names initials="M">Matthias</given-names></name><xref rid="liv70314-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="liv70314-cr-0013" contrib-type="author"><name name-style="western"><surname>Mandorfer</surname><given-names initials="M">Mattias</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2330-0017</contrib-id><xref rid="liv70314-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="liv70314-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="liv70314-cr-0014" contrib-type="author" corresp="yes"><name name-style="western"><surname>Reiberger</surname><given-names initials="T">Thomas</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4590-3583</contrib-id><xref rid="liv70314-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="liv70314-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="liv70314-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><address><email>thomas.reiberger@meduniwien.ac.at</email></address></contrib><contrib id="liv70314-cr-0015" contrib-type="author"><name name-style="western"><surname>Hofer</surname><given-names initials="BS">Benedikt Silvester</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3403-3372</contrib-id><xref rid="liv70314-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="liv70314-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="liv70314-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="liv70314-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Division of Gastroenterology and Hepatology, Department of Medicine III</named-content>
<institution>Medical University of Vienna</institution>
<city>Vienna</city>
<country country="AT">Austria</country>
</aff><aff id="liv70314-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Medicine III</named-content>
<institution>Medical University of Vienna</institution>
<city>Vienna</city>
<country country="AT">Austria</country>
</aff><aff id="liv70314-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Christian Doppler Lab for Portal Hypertension and Liver Fibrosis</named-content>
<institution>Medical University of Vienna</institution>
<city>Vienna</city>
<country country="AT">Austria</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence:</bold><break/>
Thomas Reiberger (<email>thomas.reiberger@meduniwien.ac.at</email>)<break/></corresp></author-notes><pub-date pub-type="epub"><day>03</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="ppub"><month>10</month><year>2025</year></pub-date><volume>45</volume><issue seq="130">10</issue><issue-id pub-id-type="pmc-issue-id">496084</issue-id><issue-id pub-id-type="doi">10.1111/liv.v45.10</issue-id><elocation-id>e70314</elocation-id><history><date date-type="rev-recd"><day>14</day><month>7</month><year>2025</year></date><date date-type="received"><day>24</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>21</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Liver International</italic> published by John Wiley &amp; Sons Ltd.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="LIV-45-0.pdf"/><self-uri content-type="pdf" xlink:href="file:LIV-45-0.pdf"/><abstract><title>ABSTRACT</title><sec id="liv70314-sec-0001"><title>Background and Aims</title><p>Smoking induces a proinflammatory state, yet its role in advanced chronic liver disease (ACLD) remains understudied. This study evaluated its impact on disease&#8208;driving mechanisms and clinical outcomes in ACLD patients.</p></sec><sec id="liv70314-sec-0002"><title>Methods</title><p>ACLD patients undergoing hepatic venous pressure gradient measurements from 2017 to 2021 were included. The association of smoking with biomarkers of inflammation, fibrogenesis, angiogenesis and the incidence of hepatocellular carcinoma (HCC), extrahepatic malignancies and mortality was examined.</p></sec><sec id="liv70314-sec-0003"><title>Results</title><p>Among 339 ACLD patients (66.1% men, median age: 56.8&#8201;years, MELD: 11, HVPG: 17&#8201;mmHg), 62% (<italic toggle="no">n</italic>&#8201;=&#8201;210) were ever&#8208;smokers (<italic toggle="no">n</italic>&#8201;=&#8201;78 former, <italic toggle="no">n</italic>&#8201;=&#8201;132 active). Compared to never/former smokers, active smokers exhibited significantly higher white blood cell counts (5.49 vs. former: 4.74 vs. never: 4.25&#8201;G/L; <italic toggle="no">p</italic>&#8201;&lt;&#8201;0.001) and C&#8208;reactive protein levels (CRP: 0.36 vs. former: 0.29 vs. 0.21&#8201;mg/dL; <italic toggle="no">p</italic>&#8201;=&#8201;0.035). Active smokers showed upregulated fibrogenic (TIMP&#8208;1: 364 vs. former: 324 vs. never: 278&#8201;ng/mL, <italic toggle="no">p</italic>&#8201;&lt;&#8201;0.001; P3NP: 20.9 vs. former: 15.6 vs. never: 17.2&#8201;&#956;g/L, <italic toggle="no">p</italic>&#8201;=&#8201;0.008) and angiogenic (PLGF: 21.7 vs. former: 18.2 vs. never: 19.0&#8201;pg/mL, <italic toggle="no">p</italic>&#8201;=&#8201;0.004) activity markers. Over a median follow&#8208;up of 30.4 months, ever&#8208;smokers exhibited a higher incidence of extrahepatic malignancies (SHR: 11.30; <italic toggle="no">p</italic>&#8201;=&#8201;0.019) and numerically higher HCC incidence (SHR: 2.27 <italic toggle="no">p</italic>&#8201;=&#8201;0.150; mostly evident in Child&#8208;Pugh A patients: SHR: 7.44, <italic toggle="no">p</italic>&#8201;=&#8201;0.053). All&#8208;cause or liver&#8208;related mortality risk did not differ significantly between ever&#8208;smokers and never&#8208;smokers.</p></sec><sec id="liv70314-sec-0004"><title>Conclusion</title><p>Smoking is linked to an upregulation of inflammatory, fibrogenic and angiogenic processes in ACLD and increases the risk of extrahepatic malignancies. These findings underscore the importance of strategies supporting smoking cessation in ACLD patients.</p></sec><sec id="liv70314-sec-0005"><title>Trial Registration</title><p><ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT03267615">NCT03267615</ext-link></p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="liv70314-kwd-0001">angiogenesis</kwd><kwd id="liv70314-kwd-0002">cirrhosis</kwd><kwd id="liv70314-kwd-0003">fibrogenesis</kwd><kwd id="liv70314-kwd-0004">HCC</kwd><kwd id="liv70314-kwd-0005">inflammation</kwd><kwd id="liv70314-kwd-0006">smoking</kwd></kwd-group><counts><fig-count count="2"/><table-count count="2"/><page-count count="11"/><word-count count="7600"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.2 mode:remove_FC converted:03.09.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="liv70314-cit-1001"><string-name name-style="western"><given-names>N.</given-names><surname>Dominik</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Simbrunner</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Scheiner</surname></string-name>, et al., &#8220;<article-title>Smoking Aggravates Inflammation, Fibrogenesis, Angiogenesis and Cancer Risk in Patients With Cirrhosis</article-title>,&#8221; <source>Liver International</source><volume>45</volume>, no. <issue>10</issue> (<year>2025</year>): <elocation-id>e70314</elocation-id>, <pub-id pub-id-type="doi">10.1111/liv.70314</pub-id>.<pub-id pub-id-type="pmid">40899194</pub-id><pub-id pub-id-type="pmcid">PMC12406090</pub-id></mixed-citation>
</p><fn-group id="liv70314-ntgp-0001"><fn fn-type="funding" id="liv70314-note-0001"><p>
<bold>Funding:</bold> The authors received no specific funding for this work.</p></fn><fn fn-type="generalState" id="liv70314-note-1001"><p>
<bold>Handling Editor:</bold> Luca Valenti</p></fn></fn-group></notes></front><body id="liv70314-body-0001"><p>
<boxed-text position="anchor" content-type="box" id="liv70314-blkfxd-0001" orientation="portrait"><caption><title>Summary</title></caption><p>
<list list-type="bullet" id="liv70314-list-0001"><list-item id="liv70314-li-0001"><p>Our research highlights the detrimental impact of smoking on patients with advanced chronic liver disease (ACLD).</p></list-item><list-item id="liv70314-li-0002"><p>We demonstrate that smoking is linked to an upregulation of inflammatory, fibrogenic and angiogenic processes in ACLD and increases the risk of extrahepatic malignancy.</p></list-item><list-item id="liv70314-li-0003"><p>These findings underscore the critical imperative for smoking cessation as a cornerstone in managing ACLD progression and improving patient outcomes.</p></list-item></list>
</p></boxed-text>
</p><sec><def-list list-content="abbreviations" id="liv70314-dl-0001"><title>Abbreviations</title><def-item><term id="liv70314-li-0004">ACLD</term><def id="liv70314-li-0005"><p>Advanced Chronic Liver Disease</p></def></def-item><def-item><term id="liv70314-li-0006">ACLF</term><def id="liv70314-li-0007"><p>Acute&#8208;on&#8208;Chronic Liver Failure</p></def></def-item><def-item><term id="liv70314-li-0008">ALD</term><def id="liv70314-li-0009"><p>Alcohol&#8208;Related Liver Disease</p></def></def-item><def-item><term id="liv70314-li-0010">CRP</term><def id="liv70314-li-0011"><p>C&#8208;Reactive Protein</p></def></def-item><def-item><term id="liv70314-li-0012">ELF</term><def id="liv70314-li-0013"><p>Enhanced Liver Fibrosis</p></def></def-item><def-item><term id="liv70314-li-0014">HCC</term><def id="liv70314-li-0015"><p>Hepatocellular Carcinoma</p></def></def-item><def-item><term id="liv70314-li-0016">HVPG</term><def id="liv70314-li-0017"><p>Hepatic Venous Pressure Gradient</p></def></def-item><def-item><term id="liv70314-li-0018">INR</term><def id="liv70314-li-0019"><p>International Normalised Ratio</p></def></def-item><def-item><term id="liv70314-li-0020">LBP</term><def id="liv70314-li-0021"><p>Lipopolysaccharide Binding Protein</p></def></def-item><def-item><term id="liv70314-li-0022">sVEGFR1</term><def id="liv70314-li-0023"><p>Soluble vascular endothelial growth factor&#8208;receptor 1</p></def></def-item><def-item><term id="liv70314-li-0024">MACE</term><def id="liv70314-li-0025"><p>Major Adverse Cardiovascular Events</p></def></def-item><def-item><term id="liv70314-li-0026">MASLD</term><def id="liv70314-li-0027"><p>Metabolic Dysfunction&#8208;Associated Steatotic Liver Disease</p></def></def-item><def-item><term id="liv70314-li-0028">MELD</term><def id="liv70314-li-0029"><p>Model for End&#8208;Stage Liver Disease</p></def></def-item><def-item><term id="liv70314-li-0030">NSBB</term><def id="liv70314-li-0031"><p>Nonselective Beta Blocker</p></def></def-item><def-item><term id="liv70314-li-0032">PLGF</term><def id="liv70314-li-0033"><p>Placental Growth Factor</p></def></def-item><def-item><term id="liv70314-li-0034">P3NP</term><def id="liv70314-li-0035"><p>Procollagen Type III N&#8208;Terminal Propeptide</p></def></def-item><def-item><term id="liv70314-li-0036">PY</term><def id="liv70314-li-0037"><p>Pack Years</p></def></def-item><def-item><term id="liv70314-li-0038">TIMP&#8208;1</term><def id="liv70314-li-0039"><p>Tissue Inhibitor of Metalloproteinases 1</p></def></def-item><def-item><term id="liv70314-li-0040">WBC</term><def id="liv70314-li-0041"><p>White Blood Cell Count</p></def></def-item></def-list></sec><sec id="liv70314-sec-0009"><label>1</label><title>Introduction</title><p>In 2015, tobacco smoking was the second leading risk factor for premature death and disability worldwide and has claimed over 5 million lives since 1990 [<xref rid="liv70314-bib-0001" ref-type="bibr">1</xref>]. Simultaneously, the burden of chronic liver disease, driven by factors including alcohol consumption, obesity and viral hepatitis, is increasing worldwide [<xref rid="liv70314-bib-0002" ref-type="bibr">2</xref>].</p><p>Importantly, smoking and chronic liver disease often coexist, as close to 40% of patients with advanced chronic liver disease (ACLD) are active or former smokers [<xref rid="liv70314-bib-0003" ref-type="bibr">3</xref>, <xref rid="liv70314-bib-0004" ref-type="bibr">4</xref>, <xref rid="liv70314-bib-0005" ref-type="bibr">5</xref>]. The prevalence is particularly high in patients with alcohol&#8208;related liver disease (ALD) with smoking rates being three times higher than in the general population [<xref rid="liv70314-bib-0006" ref-type="bibr">6</xref>].</p><p>Currently available clinical evidence suggests that smoking negatively affects chronic liver disease by promoting hepatocarcinogenesis [<xref rid="liv70314-bib-0007" ref-type="bibr">7</xref>, <xref rid="liv70314-bib-0008" ref-type="bibr">8</xref>, <xref rid="liv70314-bib-0009" ref-type="bibr">9</xref>] and stimulating hepatic fibrogenesis [<xref rid="liv70314-bib-0010" ref-type="bibr">10</xref>, <xref rid="liv70314-bib-0011" ref-type="bibr">11</xref>]. However, the impact of smoking on liver&#8208;related outcomes is multifaceted. In a systematic review of mortality predictors in ACLD patients, smoking was identified as an independent predictor of survival [<xref rid="liv70314-bib-0012" ref-type="bibr">12</xref>]. Consistent with this, smoking has also been shown to increase mortality in patients with metabolic dysfunction&#8208;associated steatotic liver disease (MASLD) in prospective population&#8208;based studies [<xref rid="liv70314-bib-0013" ref-type="bibr">13</xref>, <xref rid="liv70314-bib-0014" ref-type="bibr">14</xref>]. However, some studies have found that smoking is only a minor risk factor for first hepatic decompensation and a weak predictor of 6&#8208;month mortality after hospital discharge in decompensated patients [<xref rid="liv70314-bib-0015" ref-type="bibr">15</xref>, <xref rid="liv70314-bib-0016" ref-type="bibr">16</xref>], highlighting the need to assess the impact of smoking in both compensated ACLD, where liver function is still preserved, and decompensated ACLD separately.</p><p>Smoking has been identified as a key risk factor for hepatocellular carcinoma (HCC) in numerous studies and meta&#8208;analyses [<xref rid="liv70314-bib-0007" ref-type="bibr">7</xref>, <xref rid="liv70314-bib-0008" ref-type="bibr">8</xref>, <xref rid="liv70314-bib-0009" ref-type="bibr">9</xref>, <xref rid="liv70314-bib-0017" ref-type="bibr">17</xref>], yet the underlying pathomechanisms remain ill&#8208;defined. Chemicals found in tobacco are metabolised into carcinogenic molecules in the liver [<xref rid="liv70314-bib-0018" ref-type="bibr">18</xref>] and smoking is associated with immunosuppression and telomere dysfunction, two early mechanisms in cancer development [<xref rid="liv70314-bib-0019" ref-type="bibr">19</xref>, <xref rid="liv70314-bib-0020" ref-type="bibr">20</xref>]. Additionally, experimental evidence shows that inflammation plays a crucial role in fostering a tumour&#8208;promoting microenvironment [<xref rid="liv70314-bib-0021" ref-type="bibr">21</xref>]. The presence of benzene&#8212;a human carcinogen that is metabolised in the liver to toxic phenols and hydroquinone&#8212;in cigarette smoke has been shown to induce oxidative stress and DNA damage in the liver [<xref rid="liv70314-bib-0022" ref-type="bibr">22</xref>, <xref rid="liv70314-bib-0023" ref-type="bibr">23</xref>]. Since benzene exposure is widely recognised as a cause of extrahepatic malignancies, such as leukaemia [<xref rid="liv70314-bib-0024" ref-type="bibr">24</xref>], it likely contributes to smoking&#8208;induced liver injury and hepatocarcinogenesis, thereby increasing the risks of fibrosis and hepatocellular carcinoma in ACLD patients who smoke.</p><p>Profibrogenic effects of smoking in the liver have been suggested by previous studies showing that nicotine exposure can induce the activation of hepatic fibroblasts and profibrogenic pathways [<xref rid="liv70314-bib-0010" ref-type="bibr">10</xref>, <xref rid="liv70314-bib-0011" ref-type="bibr">11</xref>], as also reported for other organs [<xref rid="liv70314-bib-0011" ref-type="bibr">11</xref>]. Other potential mechanisms involve the induction of proinflammatory cytokine secretion and inflammatory cell recruitment [<xref rid="liv70314-bib-0025" ref-type="bibr">25</xref>] as well as reactive oxygen species production, that is, oxidative stress, leading to hepatocellular damage [<xref rid="liv70314-bib-0026" ref-type="bibr">26</xref>].</p><p>Despite the known risks of smoking, its role in ACLD remains underexplored, likely overshadowed by the perceived &#8216;dominant&#8217; risk associated with advanced chronic liver disease [<xref rid="liv70314-bib-0002" ref-type="bibr">2</xref>]. This study aims to provide a clearer understanding of the influence of smoking on key liver disease and cancer driving mechanisms as well as on hepatic and extrahepatic cancer rates and mortality in well&#8208;characterised ACLD patients.</p></sec><sec sec-type="methods" id="liv70314-sec-0010"><label>2</label><title>Methods</title><sec id="liv70314-sec-0011"><label>2.1</label><title>Study Population and Study Design</title><p>In this single&#8208;centre study, patients with ACLD undergoing a measurement of the hepatic venous pressure gradient (HVPG) in accordance with a standardised protocol [<xref rid="liv70314-bib-0027" ref-type="bibr">27</xref>] at the Hepatic Hemodynamic Lab at the Vienna General Hospital between January 2017 and December 2021 were included.</p><p>Inclusion criteria were: (i) age &#8805;&#8201;18&#8201;years, (ii) a verified diagnosis of ACLD, (iii) signed written informed consent and (iv) sufficient information regarding smoking status and packyears (PY). In accordance with national [<xref rid="liv70314-bib-0028" ref-type="bibr">28</xref>] and international [<xref rid="liv70314-bib-0029" ref-type="bibr">29</xref>] guidelines, the diagnosis of ACLD was either based on liver biopsy confirming advanced fibrosis/cirrhosis, a liver stiffness measurement &#8805;&#8201;10&#8201;kPa or an HVPG &gt;&#8201;5&#8201;mmHg. Exclusion criteria were: (i) prior liver transplantation or transjugular intrahepatic shunt insertion, (ii) active or prior hepatocellular carcinoma (HCC), (iii) active extrahepatic malignancy, (iv) portal vein thrombosis, (v) acute decompensation, active infection or acute&#8208;on&#8208;chronic liver failure (ACLF), (vii) nonselective beta blocker (NSBB) therapy at the time of measurement or (viii) insufficient data quality regarding baseline or follow&#8208;up.</p><p>This study follows a hybrid design, with a retrospective assessment of smoking history at baseline and a prospective evaluation of clinical outcomes.</p><p>Smoking status and PY were determined from electronic health records based on at least two independent reports to optimise accuracy and minimise recall bias. Smoking status was determined at baseline, and cessation dates documented in our records pertained to cessation prior to study inclusion. Any changes in smoking behaviour during follow&#8208;up were not assessed. To assess the potential impact of prior smoking habit modification, we conducted analyses evaluating the duration of smoking cessation in former smokers and its association with biomarkers and clinical outcomes.</p><p>All patients were systematically followed from the time of HVPG measurement onward, ensuring a prospective evaluation of primary outcomes, including MACE, HCC, extrahepatic malignancies and mortality. Routine blood samples, including those for biomarker analysis, were collected at baseline and analysed at the ISO&#8208;certified Department of Laboratory Medicine of the Vienna General Hospital, following standardised procedures.</p></sec><sec id="liv70314-sec-0012"><label>2.2</label><title>Clinical Follow&#8208;Up and Events of Interest</title><p>Patients were followed up prospectively at the liver cirrhosis outpatient clinic of the Vienna General Hospital. Furthermore, all inpatient stays during the follow&#8208;up period were documented and analysed. The primary outcome parameters of interest were (i) hepatic and extrahepatic malignancies, (ii) all&#8208;cause and liver&#8208;related mortality and (iii) major cardiovascular events (MACE) including myocardial infarction, stroke and cardiovascular death. Death was considered liver&#8208;related when occurring as a direct consequence of the underlying liver disease, including acute&#8208;on&#8208;chronic liver failure (ACLF), HCC&#8208;related mortality and major complications of portal hypertension such as variceal bleeding, spontaneous bacterial peritonitis (SBP) or hepatorenal syndrome [<xref rid="liv70314-bib-0029" ref-type="bibr">29</xref>]. Data regarding the cause and date of death were acquired from the patient's electronic health records and from a query to the national death registry (Statistik Austria).</p></sec><sec id="liv70314-sec-0013"><label>2.3</label><title>Statistical Analysis</title><p>Statistical analyses were conducted using R 4.3.1 (R Core Team, R Foundation for Statistical Computing, Vienna, Austria). Continuous variables are reported as median and interquartile range. Two group comparisons were conducted using an independent samples <italic toggle="yes">t</italic>&#8208;test or a Mann&#8211;Whitney U test, as applicable. For multiple groups, comparisons of continuous variables were performed using an analysis of variance with Tukey's multiple comparisons correction or a Kruskal&#8211;Wallis test with Bonferroni correction, as applicable. The presence of a normal distribution was assessed by visual inspection of density plots and the Shapiro&#8211;Wilk test. The correlation of two continuous variables was analysed based on the Spearman's rank correlation coefficient. Multiple linear regression models, including MELD and HVPG, modelled using restricted cubic splines with three degrees of freedom, were employed to account for the severity of liver dysfunction and portal hypertension. Categorical variables were reported as number (percentage) and compared by Pearson's Chi&#8208;squared test or Fisher's exact test.</p><p>The prognostic impact of smoking on MACE, HCC, extrahepatic malignancies, all&#8208;cause mortality and liver&#8208;related death was analysed using uni&#8208; and multivariable cause&#8208;specific Fine and Gray competing risk regression models. Death and liver transplantation were treated as competing events within the analysis of MACE, HCC and extrahepatic malignancies. Non&#8208;liver&#8211;related death and liver transplantation were considered as competing events within the analysis of liver&#8208;related mortality. For all&#8208;cause mortality, liver transplantation was treated as a competing event. Within outcome models, patients were followed from the time of HVPG measurement until the earliest occurrence of the event of interest, a competing event, or the date of last follow&#8208;up. Multivariable models were adjusted for relevant cofactors in three separate models: (i) Model 1 included MELD (Model for End&#8208;Stage Liver Disease; United Network for Organ Sharing MELD score [2016]) and HVPG; (ii) Model 2 included age and sex; (iii) Model 3 included diabetes and viral aetiology of liver disease. The presence of multicollinearity was evaluated by variance inflation factor analysis. Outcome analyses were depicted using cumulative incidence plots. The median follow&#8208;up time of the study was calculated using the reverse Kaplan&#8211;Meier method. Two&#8208;sided <italic toggle="yes">p</italic> values &lt;&#8201;0.05 were considered statistically significant.</p></sec><sec id="liv70314-sec-0014"><label>2.4</label><title>Ethical Considerations</title><p>All analyses were conducted in accordance with the 1964 Declaration of Helsinki and its later amendments, the Declaration of Istanbul and approved by the local ethics committee of the Medical University of Vienna (1262/2017). All patients signed an informed consent form prior to study inclusion.</p></sec></sec><sec sec-type="results" id="liv70314-sec-0015"><label>3</label><title>Results</title><sec id="liv70314-sec-0016"><label>3.1</label><title>Patient Cohort</title><p>During the study period, 625 ACLD patients with known smoking status underwent a reliable HVPG measurement, with 286 patients presenting at least one exclusion criterion. Thus, 339 patients were included in the final study cohort. The detailed patient selection process is shown in Figure&#160;<xref rid="liv70314-supitem-0001" ref-type="supplementary-material">S1</xref>.</p><p>Of all included patients, 66.1% were male and the median age was 56.8 (49.1&#8211;64.7) years. The median HVPG was 17 (12&#8211;20) mmHg, the median MELD was 11 (9&#8211;15) and 52.5%, 36.0% and 11.5% of patients were classified as Child&#8208;Pugh stage A, B and C at baseline respectively. At baseline, 38.9% presented without prior hepatic decompensation. With regard to smoking status, 129 patients (38.1%) were classified as never&#8208;smokers and 210 (61.9%) as ever&#8208;smokers, with 78 (23.0%) former smokers and 132 (38.9%) active smokers. With a median age of 62.4&#8201;years at study inclusion, former smokers were significantly older than never&#8208;smokers (54.0&#8201;years) and active smokers (54.4&#8201;years; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). The proportion of male patients was significantly higher in former (75.6%) and active (72.0%) smokers than never&#8208;smokers (54.3%; <italic toggle="yes">p</italic>&#8201;=&#8201;0.001). A detailed overview of all baseline characteristics is shown in Table&#160;<xref rid="liv70314-tbl-0001" ref-type="table">1</xref>.</p><table-wrap position="float" id="liv70314-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Patient characteristics stratified by smoking status.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">Full cohort <italic toggle="yes">n</italic>&#8201;=&#8201;339</th><th align="center" valign="bottom" rowspan="1" colspan="1">Never smokers <italic toggle="yes">n</italic>&#8201;=&#8201;129</th><th align="center" valign="bottom" rowspan="1" colspan="1">Former smokers <italic toggle="yes">n</italic>&#8201;=&#8201;78</th><th align="center" valign="bottom" rowspan="1" colspan="1">Active smokers <italic toggle="yes">n</italic>&#8201;=&#8201;132</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Age, years</td><td align="center" valign="top" rowspan="1" colspan="1">56.8 (49.1&#8211;64.7)</td><td align="center" valign="top" rowspan="1" colspan="1">54.0 (46.5&#8211;65.2)<xref rid="liv70314-note-0005" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">62.4 (56.4&#8211;68.6)<xref rid="liv70314-note-0004" ref-type="table-fn">*</xref>, <xref rid="liv70314-note-0006" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">54.4 (45.6&#8211;61.0)<xref rid="liv70314-note-0005" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>&lt;&#8201;0.001</bold>
</td></tr><tr><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">Sex, male</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">224 (66.1%)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">70 (54.3%)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">59 (75.6%)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">95 (72.0%)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">
<bold>0.001</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Aetiology</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">
<bold>&lt;&#8201;0.001</bold>
</td></tr><tr><td align="left" style="padding-left:10%; background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">ALD</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">158 (46.6%)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">50 (38.8%)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">33 (42.3%)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">75 (56.8%)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Viral</td><td align="center" valign="top" rowspan="1" colspan="1">56 (16.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">23 (17.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">9 (11.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">24 (18.2%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%; background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">ALD/Viral</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">21 (6.2%)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">0 (0%)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">5 (6.4%)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">16 (12.1%)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">MASLD</td><td align="center" valign="top" rowspan="1" colspan="1">30 (8.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">14 (10.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">14 (17.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (1.5%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%; background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">Cholestatic</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">20 (5.9%)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">13 (10.1%)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">4 (5.1%)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">3 (2.3%)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Other</td><td align="center" valign="top" rowspan="1" colspan="1">54 (15.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">29 (22.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">13 (16.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">12 (9.1%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">HVPG, mmHg</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">17 (12&#8211;20)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">16 (11&#8211;20)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">17 (10&#8211;21)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">17 (13&#8211;21)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">0.450</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Compensated</td><td align="center" valign="top" rowspan="1" colspan="1">132 (38.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">61 (47.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">31 (39.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">40 (30.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.019</bold>
</td></tr><tr><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">MELD</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">11 (9&#8211;15)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">11 (8&#8211;15)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">12 (9&#8211;16)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">10 (9&#8211;15)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">0.360</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Child&#8208;Pugh stage</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.861</td></tr><tr><td align="left" style="padding-left:10%; background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">A</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">178 (52.5%)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">69 (53.5%)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">41 (52.6%)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">68 (51.5%)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">B</td><td align="center" valign="top" rowspan="1" colspan="1">122 (36.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">48 (37.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">26 (33.3%)</td><td align="center" valign="top" rowspan="1" colspan="1">48 (36.4%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%; background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">C</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">39 (11.5%)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">12 (9.3%)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">11 (14.1%)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">16 (12.1%)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diabetes</td><td align="center" valign="top" rowspan="1" colspan="1">87 (25.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">35 (27.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">30 (38.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">22 (16.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.002</bold>
</td></tr><tr><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">Art. hypertension</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">109 (32.2%)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">45 (34.9%)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">38 (48.7%)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">26 (19.7%)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">
<bold>&lt;&#8201;0.001</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Albumin, g/L</td><td align="center" valign="top" rowspan="1" colspan="1">36.7 (32.6&#8211;40.2)</td><td align="center" valign="top" rowspan="1" colspan="1">36.8 (32.8&#8211;40.2)</td><td align="center" valign="top" rowspan="1" colspan="1">36.5 (32.5&#8211;40.2)</td><td align="center" valign="top" rowspan="1" colspan="1">36.7 (32.8&#8211;40.2)</td><td align="center" valign="top" rowspan="1" colspan="1">0.873</td></tr><tr><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">Bilirubin, mg/dL</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">1.06 (0.72&#8211;1.96)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">1.12 (0.75&#8211;1.95)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">1.14 (0.75&#8211;1.96)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">0.97 (0.67&#8211;1.94)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">0.242</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">INR</td><td align="center" valign="top" rowspan="1" colspan="1">1.3 (1.2&#8211;1.5)</td><td align="center" valign="top" rowspan="1" colspan="1">1.3 (1.2&#8211;1.6)</td><td align="center" valign="top" rowspan="1" colspan="1">1.3 (1.2&#8211;1.5)</td><td align="center" valign="top" rowspan="1" colspan="1">1.3 (1.2&#8211;1.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.920</td></tr><tr><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">Creatinine, mg/dL</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">0.75 (0.61&#8211;0.95)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">0.73 (0.59&#8211;0.90)<xref rid="liv70314-note-0005" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">0.82 (0.66&#8211;1.07)<xref rid="liv70314-note-0004" ref-type="table-fn">*</xref>, <xref rid="liv70314-note-0006" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">0.72 (0.60&#8211;0.88)<xref rid="liv70314-note-0005" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">
<bold>0.009</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sodium, mmol/L</td><td align="center" valign="top" rowspan="1" colspan="1">138 (136&#8211;141)</td><td align="center" valign="top" rowspan="1" colspan="1">139 (137&#8211;141)</td><td align="center" valign="top" rowspan="1" colspan="1">138 (135&#8211;140)</td><td align="center" valign="top" rowspan="1" colspan="1">139 (136&#8211;140)</td><td align="center" valign="top" rowspan="1" colspan="1">0.077</td></tr><tr><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">Platelets, G/L</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">102 (75&#8211;142)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">100 (76&#8211;132)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">99 (78&#8211;138)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">106 (70&#8211;154)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">0.649</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">WBC, G/L</td><td align="center" valign="top" rowspan="1" colspan="1">4.78 (3.30&#8211;6.35)</td><td align="center" valign="top" rowspan="1" colspan="1">4.25 (3.03&#8211;5.52)<xref rid="liv70314-note-0006" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">4.74 (3.20&#8211;5.93)<xref rid="liv70314-note-0006" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">5.49 (3.90&#8211;7.30)<xref rid="liv70314-note-0004" ref-type="table-fn">*</xref>, <xref rid="liv70314-note-0005" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>&lt;&#8201;0.001</bold>
</td></tr><tr><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">CRP, mg/dL</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">0.29 (0.12&#8211;0.68)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">0.21 (0.11&#8211;0.59)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">0.29 (0.13&#8211;0.67)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">0.36 (0.17&#8211;0.75)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">
<bold>0.035</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IL&#8208;6, mg/dL</td><td align="center" valign="top" rowspan="1" colspan="1">9.36 (5.27&#8211;17.7)</td><td align="center" valign="top" rowspan="1" colspan="1">9.61 (4.73&#8211;17.2)</td><td align="center" valign="top" rowspan="1" colspan="1">9.80 (5.47&#8211;18.8)</td><td align="center" valign="top" rowspan="1" colspan="1">8.67 (5.66&#8211;17.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.519</td></tr><tr><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">LBP, &#956;g/mL</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">6.89 (5.20&#8211;8.89)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">6.20 (4.92&#8211;8.49)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">7.32 (5.33&#8211;8.95)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">7.12 (5.45&#8211;9.40)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">0.080</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">vWF Antigen, %</td><td align="center" valign="top" rowspan="1" colspan="1">273 (210&#8211;354)</td><td align="center" valign="top" rowspan="1" colspan="1">264 (205&#8211;333)</td><td align="center" valign="top" rowspan="1" colspan="1">274 (208&#8211;349)</td><td align="center" valign="top" rowspan="1" colspan="1">287 (216&#8211;365)</td><td align="center" valign="top" rowspan="1" colspan="1">0.420</td></tr><tr><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">AST, U/L</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">42 (30&#8211;58)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">43 (32&#8211;59)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">41 (29&#8211;60)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">42 (29&#8211;56)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">0.889</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ALT, U/L</td><td align="center" valign="top" rowspan="1" colspan="1">30 (21&#8211;43)</td><td align="center" valign="top" rowspan="1" colspan="1">32 (23&#8211;46)</td><td align="center" valign="top" rowspan="1" colspan="1">31 (21&#8211;43)</td><td align="center" valign="top" rowspan="1" colspan="1">27 (19&#8211;40)</td><td align="center" valign="top" rowspan="1" colspan="1">0.073</td></tr><tr><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">ELF</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">11.4 (10.4&#8211;12.4)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">11.1 (10.3&#8211;12.2)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">11.5 (10.6&#8211;12.3)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">11.6 (10.8&#8211;12.8)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">0.090</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TIMP&#8208;1, ng/mL</td><td align="center" valign="top" rowspan="1" colspan="1">325 (245&#8211;467)</td><td align="center" valign="top" rowspan="1" colspan="1">278 (211&#8211;394)<xref rid="liv70314-note-0006" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">324 (252&#8211;434)</td><td align="center" valign="top" rowspan="1" colspan="1">364 (275&#8211;501)<xref rid="liv70314-note-0004" ref-type="table-fn">*</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>&lt;&#8201;0.001</bold>
</td></tr><tr><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">P3NP, &#956;g/L</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">18.0 (11.4&#8211;30.5)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">17.2 (10.6&#8211;28.7)<xref rid="liv70314-note-0006" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">15.6 (10.9&#8211;24.9)<xref rid="liv70314-note-0006" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">20.9 (13.6&#8211;35.0)<xref rid="liv70314-note-0004" ref-type="table-fn">*</xref>, <xref rid="liv70314-note-0005" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">
<bold>0.008</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HA, ng/mL</td><td align="center" valign="top" rowspan="1" colspan="1">223 (108&#8211;468)</td><td align="center" valign="top" rowspan="1" colspan="1">179 (96&#8211;365)</td><td align="center" valign="top" rowspan="1" colspan="1">249 (115&#8211;414)</td><td align="center" valign="top" rowspan="1" colspan="1">234 (115&#8211;540)</td><td align="center" valign="top" rowspan="1" colspan="1">0.266</td></tr><tr><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">sVEGFR1, pg/mL</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">106 (91&#8211;127)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">106 (93&#8211;121)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">103 (91&#8211;125)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">107 (89&#8211;135)</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">0.847</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PLGF, pg/mL</td><td align="center" valign="top" rowspan="1" colspan="1">19.8 (16.3&#8211;26.0)</td><td align="center" valign="top" rowspan="1" colspan="1">19.0 (14.8&#8211;22.5)<xref rid="liv70314-note-0006" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">18.2 (15.4&#8211;25.3)<xref rid="liv70314-note-0006" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">21.7 (17.9&#8211;29.1)<xref rid="liv70314-note-0004" ref-type="table-fn">*</xref>, <xref rid="liv70314-note-0005" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.004</bold>
</td></tr></tbody></table><table-wrap-foot id="liv70314-ntgp-0002"><fn id="liv70314-note-0002"><p>
<italic toggle="yes">Note:</italic> Data presented as number <italic toggle="yes">n</italic> (%) or median (IQR). Data on TIMP&#8208;1, P3NP and HA as components of the ELF test are missing in <italic toggle="yes">n</italic>&#8201;=&#8201;20 patients. Data on sFLT1 (sVEGFR1) and PLGF are missing in <italic toggle="yes">n</italic>&#8201;=&#8201;153 patients. <italic toggle="yes">p</italic> values in bold indicate statistical significance.</p></fn><fn id="liv70314-note-0003"><p>Abbreviations: ALD, alcohol&#8208;related liver disease; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C&#8208;reactive protein; ELF enhanced liver fibrosis test; HA, hyaluronic acid; HVPG, hepatic venous pressure gradient; IL&#8208;6, interleukin 6; INR, international normalised ratio; LBP, lipopolysaccharide binding protein; MASLD, metabolic&#8208;dysfunction associated steatotic liver disease; MELD, model for end&#8208;stage liver disease; P3NP, procollagen type III N&#8208;terminal propeptide; PLGF, placental growth factor; sVEGFR1, soluble vascular endothelial growth factor receptor 1; TIMP&#8208;1, tissue inhibitor of metalloproteinases 1; vWF, von Willebrand factor; WBC, white blood cell count.</p></fn><fn id="liv70314-note-0004"><label>*</label><p>
<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05 when compared to never smokers.</p></fn><fn id="liv70314-note-0005"><label>
<sup>a</sup>
</label><p>Versus former smokers.</p></fn><fn id="liv70314-note-0006"><label>
<sup>b</sup>
</label><p>Versus smokers.</p></fn></table-wrap-foot></table-wrap><p>The median number of PY in ever&#8208;smokers was 30 (19&#8211;40), with 30 (15&#8211;45) in former smokers and 30 (20&#8211;40) in active smokers. 53.8% of ever&#8208;smokers had a history of at least 30 PY, while only 8.6% reported less than 10 PY. In 78 former smokers, the median duration of smoking cessation prior to study inclusion was 12.7&#8201;years (IQR: 5.4&#8211;19.5&#8201;years). At baseline, 21% of former smokers (<italic toggle="yes">n</italic>&#8201;=&#8201;16) had quit within the last 3&#8201;years, 23% (<italic toggle="yes">n</italic>&#8201;=&#8201;18) had quit between 3 and 10&#8201;years prior and 56% (<italic toggle="yes">n</italic>&#8201;=&#8201;44) had been smoke&#8208;free for more than 10&#8201;years. During the follow&#8208;up period, no active smokers at baseline reported smoking cessation for at least 6&#8201;months.</p><p>The most prevalent underlying aetiologies were ALD in 46.6% and viral liver disease in 16.5%, while 6.2% had combined alcohol&#8208;related and viral liver disease. Among patients with viral (co&#8208;)aetiology, <italic toggle="yes">n</italic>&#8201;=&#8201;19 (33.9%) were viraemic at enrolment, while <italic toggle="yes">n</italic>&#8201;=&#8201;39 (69.6%) had achieved sustained virologic response (SVR) through antiviral therapy (for a median of 2.4&#8201;years) prior to enrolment. Across different aetiologies, ALD patients showed the highest prevalence of former/active smokers with 68.4%, compared to 58.9% in viral liver disease, 53.3% in MASLD and 35.0% in cholestatic liver diseases. Among the 158 patients with ALD aetiology, 101 (63.9%) reported abstinence for at least 6&#8201;months at baseline, while 57 (36.1%) reported occasional or ongoing alcohol consumption. When stratified by baseline smoking status within the ALD cohort, ongoing alcohol consumption at baseline was reported by a significantly higher proportion of active smokers (45.3%, <italic toggle="yes">n</italic>&#8201;=&#8201;34/75) compared to former smokers (33.3%, <italic toggle="yes">n</italic>&#8201;=&#8201;11/33) and never&#8208;smokers (24.0%, <italic toggle="yes">n</italic>&#8201;=&#8201;12/50) (<italic toggle="yes">p</italic>&#8201;=&#8201;0.043). During follow&#8208;up, relapse or continued alcohol consumption was documented in 52.0% (<italic toggle="yes">n</italic>&#8201;=&#8201;39/75) of active smokers with ALD, which was a significantly higher rate than observed in former smokers (36.4%, <italic toggle="yes">n</italic>&#8201;=&#8201;12/33) and never&#8208;smokers (30.0%, <italic toggle="yes">n</italic>&#8201;=&#8201;15/50) within the ALD cohort (<italic toggle="yes">p</italic>&#8201;=&#8201;0.033).</p></sec><sec id="liv70314-sec-0017"><label>3.2</label><title>Impact of Smoking on Disease&#8208;Driving Mechanisms in <styled-content style="fixed-case" toggle="no">ACLD</styled-content>
</title><p>While the number of patients without prior hepatic decompensation decreased gradually from 47.3% in never&#8208;smokers to 39.7% in former smokers and 30.3% in active smokers, there were no significant differences in MELD, Child&#8208;Pugh stage, or HVPG at baseline (Table&#160;<xref rid="liv70314-tbl-0001" ref-type="table">1</xref>).</p><p>Regarding systemic inflammation, active smokers showed a significantly higher white blood cell count (WBC) (5.49&#8201;G/L) compared to former smokers (4.74&#8201;G/L) or never&#8208;smokers (4.25&#8201;G/L; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). Similarly, C&#8208;reactive protein (CRP) was highest in active smokers (0.36&#8201;mg/dL vs. former: 0.29&#8201;mg/dL vs. never: 0.21&#8201;mg/dL; <italic toggle="yes">p</italic>&#8201;=&#8201;0.035). For lipopolysaccharide binding protein (LBP), median levels were markedly higher in active (7.12&#8201;&#956;g/mL) and former (7.32&#8201;&#956;g/mL) smokers as compared to never&#8208;smokers (6.20&#8201;&#956;g/mL; <italic toggle="yes">p</italic>&#8201;=&#8201;0.080) (Table&#160;<xref rid="liv70314-tbl-0001" ref-type="table">1</xref>, Figure&#160;<xref rid="liv70314-supitem-0002" ref-type="supplementary-material">S2</xref>). After including MELD and HVPG in multiple linear regression models, active smokers showed significantly higher WBC (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), CRP (<italic toggle="yes">p</italic>&#8201;=&#8201;0.015) and LBP (<italic toggle="yes">p</italic>&#8201;=&#8201;0.029) levels compared to never&#8208;smokers, while no significant differences were found between former and never&#8208;smokers. When analysing differences according to PY in active and former smokers, no significant differences in WBC, CRP or LBP were observed between &lt;&#8201;30 and &#8805;&#8201;30 PY (Table&#160;<xref rid="liv70314-supitem-0003" ref-type="supplementary-material">S1</xref>).</p><p>With regard to fibrogenesis, there was a stepwise increase in the median ELF test levels from 11.1 in never&#8208;smokers to 11.5 in former smokers and 11.6 in active smokers (<italic toggle="yes">p</italic>&#8201;=&#8201;0.090). For distinct components of the ELF test, active smokers showed significantly higher levels of both tissue inhibitor of metalloproteinases 1 (TIMP&#8208;1; 364&#8201;ng/mL vs. former: 324&#8201;ng/mL vs. never: 278&#8201;ng/mL; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) and procollagen type III N&#8208;terminal propeptide (P3NP; 20.9&#8201;&#956;g/L vs. former: 15.6&#8201;&#956;g/L vs. never: 17.2&#8201;&#956;g/L; <italic toggle="yes">p</italic>&#8201;=&#8201;0.008) (Table&#160;<xref rid="liv70314-tbl-0001" ref-type="table">1</xref>, Figure&#160;<xref rid="liv70314-supitem-0002" ref-type="supplementary-material">S2</xref>). After adjusting for MELD and HVPG, active smokers showed significantly higher ELF (<italic toggle="yes">p</italic>&#8201;=&#8201;0.027) and TIMP&#8208;1 (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) levels compared to never&#8208;smokers, while no significant differences were observed between former and never&#8208;smokers. P3NP levels did not significantly differ by smoking status. ELF components did not differ significantly in active or former smokers with &lt;&#8201;30 versus &#8805;&#8201;30 PY (Table&#160;<xref rid="liv70314-supitem-0003" ref-type="supplementary-material">S1</xref>).</p><p>Within the analysis of parameters reflecting pathological angiogenesis, active smokers showed significantly higher levels of placental growth factor (PLGF; 21.7&#8201;pg/mL) than former (18.2&#8201;pg/mL) or never&#8208;smokers (19.0&#8201;pg/mL; <italic toggle="yes">p</italic>&#8201;=&#8201;0.004). After adjusting for MELD and HVPG, active smokers showed significantly higher PLGF levels (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) compared to never&#8208;smokers, while no significant differences were observed between former and never smokers. For soluble vascular endothelial growth factor&#8208;receptor 1 (sVEGFR1), a scavenger of PLGF, no significant differences were observed (active: 107&#8201;pg/mL vs. former: 103&#8201;pg/mL vs. never 106&#8201;pg/mL; <italic toggle="yes">p</italic>&#8201;=&#8201;0.847) (Table&#160;<xref rid="liv70314-tbl-0001" ref-type="table">1</xref>, Figure&#160;<xref rid="liv70314-supitem-0002" ref-type="supplementary-material">S2</xref>). However, after stratifying the cohort according to PY, patients with &#8805;&#8201;30 PY not only showed significantly higher levels of PLGF (21.7&#8201;pg/mL vs. &lt;&#8201;30 PY: 18.7&#8201;pg/mL vs. never&#8208;smokers: 19.0&#8201;pg/mL; <italic toggle="yes">p</italic>&#8201;=&#8201;0.010) but also of sVEGFR1 (115&#8201;pg/mL vs. &lt;&#8201;30 PY: 95&#8201;pg/mL vs. never&#8208;smokers 106&#8201;pg/mL; <italic toggle="yes">p</italic>&#8201;=&#8201;0.046) (Table&#160;<xref rid="liv70314-supitem-0003" ref-type="supplementary-material">S1</xref>).</p></sec><sec id="liv70314-sec-0018"><label>3.3</label><title>Hepatocellular Carcinoma and Extrahepatic Malignancies</title><p>Over a median follow&#8208;up of 30.4 (21.2&#8211;44.6) months, 18 patients developed de novo HCC&#8212;4 occurred in never&#8208;smokers and 14 in ever&#8208;smokers, with 6 cases in former smokers and 8 in active smokers. Accordingly, in the univariable competing risk regression model (Table&#160;<xref rid="liv70314-supitem-0003" ref-type="supplementary-material">S2</xref>, Figure&#160;<xref rid="liv70314-fig-0001" ref-type="fig">1A</xref>), ever&#8208;smokers showed a nonsignificant trend toward a higher risk of de novo HCC when compared to never&#8208;smokers (subdistribution hazard ratio [SHR]: 2.27; 95% confidence interval [CI]: 0.75&#8211;6.89; <italic toggle="yes">p</italic>&#8201;=&#8201;0.150). In a subgroup analysis of Child&#8208;Pugh A patients (<italic toggle="yes">n</italic>&#8201;=&#8201;178), there was a trend toward higher risk in ever&#8208;smokers (1/69 never&#8208;smokers [1.4%] vs. 12/109 ever&#8208;smokers [11.0%]; SHR 7.44 (95% CI: 0.97&#8211;56.90; <italic toggle="yes">p</italic>&#8201;=&#8201;0.053) (Figure&#160;<xref rid="liv70314-fig-0001" ref-type="fig">1B</xref>)).</p><fig position="float" fig-type="FIGURE" id="liv70314-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Cumulative incidence of hepatocellular carcinoma in never smokers compared to ever smokers in (A) the complete study cohort and (B) Child&#8208;Pugh A patients. Abbreviations: HCC, hepatocellular carcinoma; SHR, subdistribution hazard ratio.</p></caption><graphic position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="LIV-45-0-g002.jpg"/></fig><p>In the multivariable competing risk regression models (Table&#160;<xref rid="liv70314-supitem-0003" ref-type="supplementary-material">S2</xref>) adjusted for viral aetiology, smoking remained numerically associated with a higher incidence for HCC with an aSHR 2.15 (<italic toggle="yes">p</italic>&#8201;=&#8201;0.180).</p><p>There was neither an association of HCC occurrence with the number of PY in ever&#8208;smokers (SHR per PY: 0.99; 95% CI: 0.97&#8211;1.01; <italic toggle="yes">p</italic>&#8201;=&#8201;0.570; Table&#160;<xref rid="liv70314-supitem-0003" ref-type="supplementary-material">S3</xref>) or active smokers (SHR per PY: 1.00; 95% CI: 0.96&#8211;1.04; <italic toggle="yes">p</italic>&#8201;=&#8201;0.880).</p><p>Extrahepatic malignancies occurred in 18 patients during follow&#8208;up, with one case in a never&#8208;smoker, nine in former smokers and eight in active smokers. Among the 26 patients who underwent liver transplantation within our cohort, no de novo extrahepatic malignancy was observed during their follow&#8208;up period. The only extrahepatic malignancy in never&#8208;smokers was a cholangiocarcinoma, which developed in a patient with primary sclerosing cholangitis. In contrast, the majority of the 17 de novo extrahepatic malignancies that occurred in ever&#8208;smokers were found in the respiratory tract (<italic toggle="yes">n</italic>&#8201;=&#8201;3 lung cancer, <italic toggle="yes">n</italic>&#8201;=&#8201;1 cancer of the vocal folds), the oropharynx and tongue (<italic toggle="yes">n</italic>&#8201;=&#8201;3), the bladder (<italic toggle="yes">n</italic>&#8201;=&#8201;2) and the rectum (<italic toggle="yes">n</italic>&#8201;=&#8201;2).</p><p>In the univariable competing risk regression model, ever&#8208;smokers had a significantly higher risk of de novo extrahepatic malignancies compared to never&#8208;smokers, both in the overall cohort (SHR: 11.30; 95% CI: 1.49&#8211;85.90; <italic toggle="yes">p</italic>&#8201;=&#8201;0.019) (Table&#160;<xref rid="liv70314-tbl-0002" ref-type="table">2</xref>, Figure&#160;<xref rid="liv70314-fig-0002" ref-type="fig">2A</xref>) and in the subgroup of Child&#8208;Pugh A patients (SHR: 7.13; 95% CI: 0.92&#8211;55.40; <italic toggle="yes">p</italic>&#8201;=&#8201;0.061) (Figure&#160;<xref rid="liv70314-fig-0002" ref-type="fig">2B</xref>). In the multivariable models (Table&#160;<xref rid="liv70314-tbl-0002" ref-type="table">2</xref>) adjusted for age and MELD, smoking remained significantly associated with a higher risk for extrahepatic malignancies (aSHR: 11.03; <italic toggle="yes">p</italic>&#8201;=&#8201;0.021).</p><table-wrap position="float" id="liv70314-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Smoking and risk of extrahepatic malignancy using competing risk regression analysis.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" colspan="3" valign="bottom" rowspan="1">Univariable analysis</th><th align="center" colspan="3" valign="bottom" rowspan="1">Multivariable model 1 adjusted for MELD</th><th align="center" colspan="3" valign="bottom" rowspan="1">Multivariable model 2 adjusted for diabetes</th><th align="center" colspan="3" valign="bottom" rowspan="1">Multivariable model 3 adjusted for ALD</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">SHR</th><th align="center" valign="bottom" rowspan="1" colspan="1">95% CI</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">aSHR</th><th align="center" valign="bottom" rowspan="1" colspan="1">95% CI</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">aSHR</th><th align="center" valign="bottom" rowspan="1" colspan="1">95% CI</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">aSHR</th><th align="center" valign="bottom" rowspan="1" colspan="1">95% CI</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Ever smoking, yes</td><td align="center" valign="top" rowspan="1" colspan="1">11.30</td><td align="center" valign="top" rowspan="1" colspan="1">1.49&#8211;85.90</td><td align="center" valign="top" rowspan="1" colspan="1">0.019</td><td align="center" valign="top" rowspan="1" colspan="1">11.03</td><td align="center" valign="top" rowspan="1" colspan="1">1.43&#8211;84.31</td><td align="center" valign="top" rowspan="1" colspan="1">0.021</td><td align="center" valign="top" rowspan="1" colspan="1">10.82</td><td align="center" valign="top" rowspan="1" colspan="1">1.43&#8211;81.99</td><td align="center" valign="top" rowspan="1" colspan="1">0.021</td><td align="center" valign="top" rowspan="1" colspan="1">10.72</td><td align="center" valign="top" rowspan="1" colspan="1">1.42&#8211;81.23</td><td align="center" valign="top" rowspan="1" colspan="1">0.022</td></tr><tr><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">Age, per year</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">1.04</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">1.00&#8211;1.09</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">0.052</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">1.05</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">1.00&#8211;1.10</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">0.076</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">1.04</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">0.99&#8211;1.10</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">0.120</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">1.04</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">0.99&#8211;1.10</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">0.094</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MELD, per point</td><td align="center" valign="top" rowspan="1" colspan="1">0.97</td><td align="center" valign="top" rowspan="1" colspan="1">0.87&#8211;0.1.08</td><td align="center" valign="top" rowspan="1" colspan="1">0.520</td><td align="center" valign="top" rowspan="1" colspan="1">0.97</td><td align="center" valign="top" rowspan="1" colspan="1">0.86&#8211;1.06</td><td align="center" valign="top" rowspan="1" colspan="1">0.410</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">Diabetes, present</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">1.50</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">0.57&#8211;3.98</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">0.410</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1"/><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1"/><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1"/><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">1.13</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">0.39&#8211;3.26</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1">0.830</td><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1"/><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1"/><td align="center" style="background-color:#F2F2F2" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ALD, vs. other aetiologies</td><td align="center" valign="top" rowspan="1" colspan="1">1.48</td><td align="center" valign="top" rowspan="1" colspan="1">0.59&#8211;3.74</td><td align="center" valign="top" rowspan="1" colspan="1">0.410</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1.22</td><td align="center" valign="top" rowspan="1" colspan="1">0.49&#8211;3.05</td><td align="center" valign="top" rowspan="1" colspan="1">0.670</td></tr></tbody></table><table-wrap-foot id="liv70314-ntgp-0003"><fn id="liv70314-note-0007"><p>
<italic toggle="yes">Note:</italic> Uni&#8208; and multivariable Fine&#8211;Gray competing risk regression models assessing predictors of de novo extrahepatic malignancy with death and liver transplantation as competing events. Follow&#8208;up was censored at the earliest occurrence of liver transplantation or death.</p></fn><fn id="liv70314-note-0008"><p>Abbreviations: ALD, alcohol&#8208;related liver disease; aSHR, adjusted subdistribution hazard ratio; MELD, model for end&#8208;stage liver disease; SHR, subdistribution hazard ratio.</p></fn></table-wrap-foot></table-wrap><fig position="float" fig-type="FIGURE" id="liv70314-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Cumulative incidence of extrahepatic malignancy in never smokers compared to ever smokers in (A) the complete study cohort and (B) Child&#8208;Pugh A patients. Abbreviations: SHR, subdistribution hazard ratio.</p></caption><graphic position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="LIV-45-0-g001.jpg"/></fig><p>With regard to the impact of PY, there was no association with extrahepatic malignancies in ever&#8208;smokers (SHR per PY: 1.00; 95% CI: 0.99&#8211;1.02; <italic toggle="yes">p</italic>&#8201;=&#8201;0.770; Table&#160;<xref rid="liv70314-supitem-0003" ref-type="supplementary-material">S4</xref>) or active smokers (aSHR per PY: 1.00; 95% CI: 0.96&#8211;1.03; <italic toggle="yes">p</italic>&#8201;=&#8201;0.890) in a multivariable model including age. Furthermore, in former smokers, the risk did not differ significantly when compared to active smokers (SHR former vs. active: 1.67; 95% CI: 0.67&#8211;4.24; <italic toggle="yes">p</italic>&#8201;=&#8201;0.280) and the duration of being smoke&#8208;free was not associated with a decreased risk (SHR per year: 1.01; 95% CI: 0.99&#8211;1.03; <italic toggle="yes">p</italic>&#8201;=&#8201;0.430).</p></sec><sec id="liv70314-sec-0019"><label>3.4</label><title>Major Adverse Cardiovascular Events and Mortality</title><p>At baseline, the proportion of patients with preexisting coronary artery disease and prior MACE was significantly higher in ever&#8208;smokers when compared to never&#8208;smokers with 16.2% versus 2.3% for coronary artery disease (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) and 7.1% versus 2.3% for prior MACE (<italic toggle="yes">p</italic>&#8201;=&#8201;0.055). During follow&#8208;up, nine patients experienced MACE including <italic toggle="yes">n</italic>&#8201;=&#8201;3 myocardial infarctions, <italic toggle="yes">n</italic>&#8201;=&#8201;2 strokes and <italic toggle="yes">n</italic>&#8201;=&#8201;4 cardiovascular deaths, with two and seven MACE occurring in never&#8208;smokers and in ever&#8208;smokers (<italic toggle="yes">n</italic>&#8201;=&#8201;4 in former smokers; <italic toggle="yes">n</italic>&#8201;=&#8201;3 in active smokers) respectively. Ever&#8208;smokers had a numerically higher risk of MACE when compared to never&#8208;smokers (SHR: 2.18; 95% CI: 0.46&#8211;10.40; <italic toggle="yes">p</italic>&#8201;=&#8201;0.330), which remained true after including preexisting coronary artery disease in a multivariable model (SHR: 1.93; 95% CI: 0.40&#8211;9.38; <italic toggle="yes">p</italic>&#8201;=&#8201;0.420). Furthermore, the number of PY in ever&#8208;smokers was linked to a numerically higher risk of MACE (SHR per PY: 1.01; 95% CI: 0.99&#8211;1.03; <italic toggle="yes">p</italic>&#8201;=&#8201;0.470).</p><p>During the study period, 80 patients died, with 55 of these deaths being liver&#8208;related. In never and ever&#8208;smokers, 28 (21.7%; <italic toggle="yes">n</italic>&#8201;=&#8201;21 liver&#8208;related) and 52 (24.8%; <italic toggle="yes">n</italic>&#8201;=&#8201;34 liver related) died respectively. In the univariable competing risk regression model, ever&#8208;smokers did not show a significantly higher risk of all&#8208;cause mortality when compared to never&#8208;smokers, both in the overall cohort (SHR: 1.18; 95% CI: 0.75&#8211;1.86; <italic toggle="yes">p</italic>&#8201;=&#8201;0.490) and in the subgroup of Child&#8208;Pugh A patients (SHR: 1.36; 95% CI: 0.64&#8211;2.87; <italic toggle="yes">p</italic>&#8201;=&#8201;0.430). Both in ever&#8208;smokers (SHR per PY: 1.00; 95% CI: 0.99&#8211;1.01; <italic toggle="yes">p</italic>&#8201;=&#8201;0.790) and active smokers (SHR per PY: 0.99; 95% CI: 0.97&#8211;1.01; <italic toggle="yes">p</italic>&#8201;=&#8201;0.300), the number of PY was not significantly linked to an altered risk of all&#8208;cause mortality and the duration of being smoke&#8208;free was not associated with a decreased risk (SHR per year: 0.99; 95% CI: 0.97&#8211;1.01; <italic toggle="yes">p</italic>&#8201;=&#8201;0.420). Similarly, ever&#8208;smokers did not have a higher risk of liver&#8208;related mortality when compared to never&#8208;smokers (SHR: 1.00; 95% CI: 0.58&#8211;1.72; <italic toggle="yes">p</italic>&#8201;=&#8201;1.000) and the number of PY in ever&#8208;smokers was not linked to a higher risk (SHR per PY: 1.00; 95% CI: 0.99&#8211;1.01; <italic toggle="yes">p</italic>&#8201;=&#8201;0.920).</p></sec></sec><sec sec-type="discussion" id="liv70314-sec-0020"><label>4</label><title>Discussion</title><p>Despite the widely known risks associated with tobacco smoking, its role in ACLD remains understudied. Smoking has negative effects on innate and adaptive immunity [<xref rid="liv70314-bib-0030" ref-type="bibr">30</xref>], both of which are already impaired in ACLD due to cirrhosis&#8208;associated immune dysfunction, as characterised by systemic inflammation and compromised immune function [<xref rid="liv70314-bib-0031" ref-type="bibr">31</xref>]. In our study, active smokers exhibited significantly higher WBC and CRP levels compared to former and never&#8208;smokers. Furthermore, the presence of elevated LBP levels in smokers indicates increased bacterial translocation, which has been previously linked to hepatic fibrogenesis [<xref rid="liv70314-bib-0032" ref-type="bibr">32</xref>] and liver disease progression in ACLD [<xref rid="liv70314-bib-0033" ref-type="bibr">33</xref>, <xref rid="liv70314-bib-0034" ref-type="bibr">34</xref>]. Thus, smoking may further increase the already elevated risk of bacterial infections in ACLD patients, which can significantly worsen the prognosis [<xref rid="liv70314-bib-0034" ref-type="bibr">34</xref>, <xref rid="liv70314-bib-0035" ref-type="bibr">35</xref>].</p><p>The role of smoking in promoting fibrogenesis is well supported by experimental evidence [<xref rid="liv70314-bib-0010" ref-type="bibr">10</xref>, <xref rid="liv70314-bib-0011" ref-type="bibr">11</xref>], yet clinical data obtained from ACLD patients are scarce. In our study, active smokers exhibited significantly higher levels of TIMP&#8208;1 and P3NP compared to former and never&#8208;smokers, indicating a link between active smoking and increased fibrogenesis. Additionally, ELF test levels progressively increased from never&#8208;smokers to former and active smokers. Potential underlying mechanisms for smoking&#8208;induced fibrogenesis include transforming growth factor&#8208;beta&#8208;1 release [<xref rid="liv70314-bib-0035" ref-type="bibr">35</xref>], an increase in proinflammatory cytokines [<xref rid="liv70314-bib-0036" ref-type="bibr">36</xref>] and reactive oxygen species production [<xref rid="liv70314-bib-0026" ref-type="bibr">26</xref>], all of which promote fibroblast activation and an increased production of extracellular matrix proteins [<xref rid="liv70314-bib-0010" ref-type="bibr">10</xref>, <xref rid="liv70314-bib-0011" ref-type="bibr">11</xref>]. Interestingly, despite the evidence of enhanced fibrogenic activity in active smokers through elevated serum fibrogenesis markers, HVPG and liver stiffness were similar across smoking groups. The lack of correlation in surrogates of (static) fibrosis severity on cross&#8208;sectional assessment does, however, not preclude that smoking triggers (active) fibrogenic processes and thereby impacts on long&#8208;term liver disease progression.</p><p>In addition, smoking was associated with increased levels of PLGF in our cohort, indicating enhanced angiogenic activity. PLGF, a member of the vascular endothelial growth factor family, is involved in pathological angiogenesis by enhancing endothelial cell proliferation and the growth and maturation of blood vessels [<xref rid="liv70314-bib-0037" ref-type="bibr">37</xref>]. Angiogenesis plays a critical role in liver disease progression [<xref rid="liv70314-bib-0038" ref-type="bibr">38</xref>] and is essential in the development and progression of HCC, a prototypical hypervascular tumour [<xref rid="liv70314-bib-0039" ref-type="bibr">39</xref>].</p><p>Regarding malignancies, our study found a significant association between smoking and extrahepatic malignancies in ACLD patients. While we observed a numerical increase in HCC incidence among ever&#8208;smokers compared to never&#8208;smokers, this association did not reach statistical significance in our cohort. This trend aligns with previous meta&#8208;analyses and cohort studies that have identified smoking as a risk factor for HCC (7&#8211;9), though our study may have been underpowered to detect a significant difference. The strongest evidence from our study relates to the effects of smoking on inflammatory, fibrogenic and angiogenic pathways, which may contribute to cancer risk in the long term.</p><p>Furthermore, our study observed a significant association between viral hepatitis and HCC development. This association persists even though a substantial proportion of our viral hepatitis patients (<italic toggle="yes">n</italic>&#8201;=&#8201;39, 69.6%) had achieved SVR prior to enrolment. This highlights that SVR does not eliminate the risk of HCC, particularly in patients who have already progressed to ACLD [<xref rid="liv70314-bib-0040" ref-type="bibr">40</xref>]. The persistent HCC risk after viral eradication, thus, continues to contribute to the observed association between viral aetiology and HCC in our ACLD cohort.</p><p>Additionally, smoking was associated with a higher incidence of extrahepatic malignancies, including cancers of the respiratory and urinary tract. These results highlight the broad carcinogenic potential of smoking, impacting both hepatic and extrahepatic sites. It is also important to consider the concept of latency, particularly in former smokers. While smoking cessation is undoubtedly beneficial, the precise kinetics of the regression of smoking&#8208;induced detrimental effects in ACLD remain complex. Our data show no significant correlation between the duration of smoking cessation and improvements in markers of inflammation, fibrogenesis or angiogenesis among former smokers. This observation can be interpreted in two ways: Either the pro&#8208;inflammatory, pro&#8208;fibrogenic and pro&#8208;angiogenic effects persist for a considerable time, implying a delayed reversibility, or conversely, the most substantial benefits occur relatively quickly after cessation, making further incremental improvements with prolonged abstinence less discernible in this advanced disease setting. Indeed, the broader carcinogenic potential of toxicants, including those from cigarette smoke, is further highlighted by a prospective study [<xref rid="liv70314-bib-0041" ref-type="bibr">41</xref>] showing long&#8208;term occupational toxicant exposure linked to increased ACLD/HCC risk. Both interpretations underscore the critical importance of early and sustained smoking cessation in ACLD patients, warranting future studies with longer follow&#8208;up.</p><p>Interestingly, in our cohort, ever&#8208;smokers did not show a significantly increased risk of all&#8208;cause or liver&#8208;related mortality. This may reflect that ACLD itself, as a severe and progressive disease, often represents the main determinant of clinical outcomes, thereby narrowing the &#8216;detrimental impact window&#8217; for smoking's additional impact. Further explanations include our cohort's advanced disease state, a potentially insufficient median 30.4&#8208;month follow&#8208;up and the high comorbidity prevalence that might dilute smoking's relative mortality contribution.</p><p>While our findings are based on a thoroughly characterised cohort of ACLD patients, some limitations need to be acknowledged: First, the reliance on self&#8208;reported smoking data without biochemical verification (e.g., cotinine levels) may introduce bias. Nevertheless, all patients without sufficient information on smoking status and PY were excluded, thus limiting the impact of this limitation. Second, other lifestyle factors such as physical activity and diet were not documented, which could confound the results. Third, the absence of observed dynamic changes in smoking status during the follow&#8208;up period is a limitation. Interestingly, our analysis did not identify male sex as a significant risk factor for HCC development despite its well&#8208;established role in hepatocarcinogenesis [<xref rid="liv70314-bib-0042" ref-type="bibr">42</xref>]. This discrepancy likely stems from our limited sample size, the pre&#8208;selection of an ACLD cohort or the predominance of alcohol&#8208;related aetiology. Lastly, our cohort only included a comparably low number of patients with low PY exposure, thus limiting any potential analyses regarding the impact of low&#8208;level smoking.</p><p>Given the detrimental effects of smoking on inflammation, fibrogenesis, angiogenesis and cancer risk, smoking cessation should be a priority in the management of ACLD patients. Integrating smoking cessation programmes into routine patient care could not only significantly reduce disease progression and cancer rates but also improve clinical outcomes and survival. Moreover, addressing smoking&#8208;related risks in ACLD patients through targeted therapies and lifestyle interventions may further enhance their overall health and quality of life.</p><p>In conclusion, smoking significantly aggravates inflammation, fibrogenesis and angiogenesis in patients with ACLD, and is associated with an increased risk of extrahepatic malignancies. These biological mechanisms are linked to hepatocarcinogenesis and thus likely contribute to hepatic cancer risk, though this association did not reach statistical significance in our cohort. Our findings emphasise the need for robust smoking cessation efforts and comprehensive lifestyle management in the care of liver disease patients.</p></sec><sec id="liv70314-sec-0021"><title>Author Contributions</title><p>All authors contributed either to the study concept and design (N.D., T.R. and B.S.H.) and/or data acquisition (all authors), analysis (N.D., T.R. and B.S.H.) or interpretation (all authors). N.D., T.R. and B.S.H. drafted the manuscript, which was critically revised by all other authors. All authors read and approved the final manuscript.</p></sec><sec sec-type="COI-statement" id="liv70314-sec-0023"><title>Disclosure</title><p>
<bold>N.D</bold>. received travel support from Gilead. <bold>B.Si</bold>. received travel support from AbbVie, Gilead and Falk. <bold>B.Sc</bold>. received travel support from AbbVie, Ipsen and Gilead. <bold>M.S</bold>. received travel support from MSD, Sandoz, BMS, AbbVie and Gilead; and speaking honoraria from BMS and Gilead. <bold>L.H</bold>. has nothing to disclose. <bold>M.J</bold>. served as speaker and/or consultant for Gilead. <bold>L.B</bold>. received speaking fees from Chiesi, and Gilead. <bold>G.S</bold>. received travel support from Amgen. <bold>G.K</bold>. has nothing to disclose. <bold>C.S</bold>. has nothing to disclose. <bold>M.T</bold>. received grant support from Albireo, Alnylam, Cymabay, Falk, Genentech, Gilead, Intercept, MSD, Takeda and UltraGenyx, honoraria for consulting from AbbVie, Albireo, Agomab, Boehringer Ingelheim, BiomX, Chemomab, Dexoligo Therapeutics, Falk, Genfit, Gilead, GSK, Hightide, Intercept, Ipsen, Jannsen, MSD, Novartis, Phenex, Pliant, Regulus, Siemens and Shire, speaker fees from Albireo, Boehringer Ingelheim, Bristol&#8208;Myers Squibb, Falk, Gilead, Ipsen, Intercept, MSD and Madrigal, as well as travel support from AbbVie, Falk, Gilead, Jannsen and Intercept. He is also co&#8208;inventor of patents on the medical use of 24&#8208;norursodeoxycholic acid filed by the Medical University of Graz. <bold>M.P</bold>. received speaker honoraria from Bayer, BMS, Eisai, Ipsen, Lilly, MSD and Roche; he is a consultant/advisory board member for AstraZeneca, Bayer, BMS, Eisai, Ipsen, Lilly, MSD and Roche; he received grants from AstraZeneca, Bayer, BMS, Eisai and Roche; he received travel support from Bayer, BMS, Ipsen and Roche. <bold>M.M</bold>. served as a speaker and/or consultant and/or advisory board member for AbbVie, Collective Acumen, Gilead, Takeda and W. L. Gore &amp; Associates and received travel support from AbbVie and Gilead. <bold>T.R</bold>. received grant support from AbbVie, Boehringer&#8208;Ingelheim, Gilead, Intercept, MSD, Myr Pharmaceuticals, Philips Healthcare, Pliant, Siemens and W. L. Gore &amp; Associates; speaking honoraria from AbbVie, Gilead, Gore, Intercept, Roche and MSD; consulting/advisory board fees from AbbVie, Bayer, Boehringer&#8208;Ingelheim, Gilead, Intercept, MSD and Siemens; and travel support from AbbVie, Boehringer&#8208;Ingelheim, Gilead and Roche. <bold>B.S.H</bold>. received travel support from Ipsen and Falk.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="liv70314-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Figure S1:</bold> liv70314&#8208;sup&#8208;0001&#8208;FigureS1.pdf.</p></caption><media xlink:href="LIV-45-0-s002.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="liv70314-supitem-0002" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Figure S2:</bold> liv70314&#8208;sup&#8208;0002&#8208;FigureS2.pdf.</p></caption><media xlink:href="LIV-45-0-s003.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="liv70314-supitem-0003" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Data S1:</bold> liv70314&#8208;sup&#8208;0003&#8208;DataS1.docx.</p></caption><media xlink:href="LIV-45-0-s001.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="liv70314-sec-0022"><title>Acknowledgements</title><p>The financial co&#8208;support by the Austrian Federal Ministry for Digital and Economic Affairs, the National Foundation for Research, Technology and Development, the Christian Doppler Research Association and Boehringer Ingelheim is gratefully acknowledged. Furthermore, we would like to thank Kerstin Zinober for her continued support in the Vienna Cirrhosis Study (VICIS), as well as the nurses of the Vienna Hepatic Hemodynamic Laboratory for their professional assistance and care for the patients during the HVPG measurements. N/A</p></ack><sec sec-type="data-availability" id="liv70314-sec-0025"><title>Data Availability Statement</title><p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></sec><ref-list content-type="cited-references" id="liv70314-bibl-0001"><title>References</title><ref id="liv70314-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="liv70314-cit-0001"><article-title>Global, Regional, and National Comparative Risk Assessment of 79 Behavioural, Environmental and Occupational, and Metabolic Risks or Clusters of Risks, 1990&#8208;2015: A Systematic Analysis for the Global Burden of Disease Study 2015</article-title>,&#8221; <source>Lancet</source><volume>388</volume>, no. <issue>10053</issue> (<year>2016</year>): <fpage>1659</fpage>&#8211;<lpage>1724</lpage>.<pub-id pub-id-type="pmid">27733284</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(16)31679-8</pub-id><pub-id pub-id-type="pmcid">PMC5388856</pub-id></mixed-citation></ref><ref id="liv70314-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="liv70314-cit-0002"><string-name name-style="western"><given-names>L.</given-names><surname>Pimpin</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Cortez&#8208;Pinto</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Negro</surname></string-name>, et&#160;al., &#8220;<article-title>Burden of Liver Disease in Europe: Epidemiology and Analysis of Risk Factors to Identify Prevention Policies</article-title>,&#8221; <source>Journal of Hepatology</source><volume>69</volume>, no. <issue>3</issue> (<year>2018</year>): <fpage>718</fpage>&#8211;<lpage>735</lpage>.<pub-id pub-id-type="pmid">29777749</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2018.05.011</pub-id></mixed-citation></ref><ref id="liv70314-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="liv70314-cit-0003"><string-name name-style="western"><given-names>M.</given-names><surname>Xiong</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Yang</surname></string-name>, et&#160;al., &#8220;<article-title>Impacts of Cigarette Smoking on Liver Fibrosis and Its Regression Under Therapy in Male Patients With Chronic Hepatitis B</article-title>,&#8221; <source>Liver International</source><volume>39</volume>, no. <issue>8</issue> (<year>2019</year>): <fpage>1428</fpage>&#8211;<lpage>1436</lpage>.<pub-id pub-id-type="pmid">30920714</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/liv.14108</pub-id></mixed-citation></ref><ref id="liv70314-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="liv70314-cit-0004"><string-name name-style="western"><given-names>I. D.</given-names><surname>Munsterman</surname></string-name>, <string-name name-style="western"><given-names>M. M.</given-names><surname>Smits</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Andriessen</surname></string-name>, et&#160;al., &#8220;<article-title>Smoking Is Associated With Severity of Liver Fibrosis but Not With Histological Severity in Nonalcoholic Fatty Liver Disease. Results From a Cross&#8208;Sectional Study</article-title>,&#8221; <source>Scandinavian Journal of Gastroenterology</source><volume>52</volume>, no. <issue>8</issue> (<year>2017</year>): <fpage>881</fpage>&#8211;<lpage>885</lpage>.<pub-id pub-id-type="pmid">28446050</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/00365521.2017.1315169</pub-id></mixed-citation></ref><ref id="liv70314-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="liv70314-cit-0005"><string-name name-style="western"><given-names>C. O.</given-names><surname>Zein</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Beatty</surname></string-name>, <string-name name-style="western"><given-names>A. B.</given-names><surname>Post</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Logan</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Debanne</surname></string-name>, and <string-name name-style="western"><given-names>A. J.</given-names><surname>McCullough</surname></string-name>, &#8220;<article-title>Smoking and Increased Severity of Hepatic Fibrosis in Primary Biliary Cirrhosis: A Cross Validated Retrospective Assessment</article-title>,&#8221; <source>Hepatology</source><volume>44</volume>, no. <issue>6</issue> (<year>2006</year>): <fpage>1564</fpage>&#8211;<lpage>1571</lpage>.<pub-id pub-id-type="pmid">17133468</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hep.21423</pub-id></mixed-citation></ref><ref id="liv70314-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="liv70314-cit-0006"><string-name name-style="western"><given-names>R. A.</given-names><surname>Grucza</surname></string-name> and <string-name name-style="western"><given-names>L. J.</given-names><surname>Bierut</surname></string-name>, &#8220;<article-title>Co&#8208;Occurring Risk Factors for Alcohol Dependence and Habitual Smoking: Update on Findings From the Collaborative Study on the Genetics of Alcoholism</article-title>,&#8221; <source>Alcohol Research &amp; Health</source><volume>29</volume>, no. <issue>3</issue> (<year>2006</year>): <fpage>172</fpage>&#8211;<lpage>178</lpage>.<pub-id pub-id-type="pmid">17373405</pub-id><pub-id pub-id-type="pmcid">PMC6527048</pub-id></mixed-citation></ref><ref id="liv70314-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="liv70314-cit-0007"><string-name name-style="western"><given-names>J. L.</given-names><surname>Petrick</surname></string-name>, <string-name name-style="western"><given-names>P. T.</given-names><surname>Campbell</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Koshiol</surname></string-name>, et&#160;al., &#8220;<article-title>Tobacco, Alcohol Use and Risk of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: The Liver Cancer Pooling Project</article-title>,&#8221; <source>British Journal of Cancer</source><volume>118</volume>, no. <issue>7</issue> (<year>2018</year>): <fpage>1005</fpage>&#8211;<lpage>1012</lpage>.<pub-id pub-id-type="pmid">29520041</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41416-018-0007-z</pub-id><pub-id pub-id-type="pmcid">PMC5931109</pub-id></mixed-citation></ref><ref id="liv70314-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="liv70314-cit-0008"><string-name name-style="western"><given-names>Y.&#8208;C. A.</given-names><surname>Lee</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Cohet</surname></string-name>, <string-name name-style="western"><given-names>Y.&#8208;C.</given-names><surname>Yang</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Stayner</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Hashibe</surname></string-name>, and <string-name name-style="western"><given-names>K.</given-names><surname>Straif</surname></string-name>, &#8220;<article-title>Meta&#8208;Analysis of Epidemiologic Studies on Cigarette Smoking and Liver Cancer</article-title>,&#8221; <source>International Journal of Epidemiology</source><volume>38</volume>, no. <issue>6</issue> (<year>2009</year>): <fpage>1497</fpage>&#8211;<lpage>1511</lpage>.<pub-id pub-id-type="pmid">19720726</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ije/dyp280</pub-id></mixed-citation></ref><ref id="liv70314-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="liv70314-cit-0009"><string-name name-style="western"><given-names>O.</given-names><surname>Abdel&#8208;Rahman</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Helbling</surname></string-name>, <string-name name-style="western"><given-names>O.</given-names><surname>Sch&#246;b</surname></string-name>, et&#160;al., &#8220;<article-title>Cigarette Smoking as a Risk Factor for the Development of and Mortality From Hepatocellular Carcinoma: An Updated Systematic Review of 81 Epidemiological Studies</article-title>,&#8221; <source>Journal of Evidence&#8208;Based Medicine</source><volume>10</volume>, no. <issue>4</issue> (<year>2017</year>): <fpage>245</fpage>&#8211;<lpage>254</lpage>.<pub-id pub-id-type="pmid">28891275</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jebm.12270</pub-id></mixed-citation></ref><ref id="liv70314-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="liv70314-cit-0010"><string-name name-style="western"><given-names>K.</given-names><surname>Jensen</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Nizamutdinov</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Guerrier</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Afroze</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Dostal</surname></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Glaser</surname></string-name>, &#8220;<article-title>General Mechanisms of Nicotine&#8208;Induced Fibrogenesis</article-title>,&#8221; <source>FASEB Journal</source><volume>26</volume>, no. <issue>12</issue> (<year>2012</year>): <fpage>4778</fpage>&#8211;<lpage>4787</lpage>.<pub-id pub-id-type="pmid">22906950</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1096/fj.12-206458</pub-id><pub-id pub-id-type="pmcid">PMC3509054</pub-id></mixed-citation></ref><ref id="liv70314-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="liv70314-cit-0011"><string-name name-style="western"><given-names>D. C.</given-names><surname>Rockey</surname></string-name>, <string-name name-style="western"><given-names>P. D.</given-names><surname>Bell</surname></string-name>, and <string-name name-style="western"><given-names>J. A.</given-names><surname>Hill</surname></string-name>, &#8220;<article-title>Fibrosis &#8211; A Common Pathway to Organ Injury and Failure</article-title>,&#8221; <source>New England Journal of Medicine</source><volume>372</volume>, no. <issue>12</issue> (<year>2015</year>): <fpage>1138</fpage>&#8211;<lpage>1149</lpage>.<pub-id pub-id-type="pmid">25785971</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMra1300575</pub-id></mixed-citation></ref><ref id="liv70314-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="liv70314-cit-0012"><string-name name-style="western"><given-names>G.</given-names><surname>D'Amico</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Garcia&#8208;Tsao</surname></string-name>, and <string-name name-style="western"><given-names>L.</given-names><surname>Pagliaro</surname></string-name>, &#8220;<article-title>Natural History and Prognostic Indicators of Survival in Cirrhosis: A Systematic Review of 118 Studies</article-title>,&#8221; <source>Journal of Hepatology</source><volume>44</volume>, no. <issue>1</issue> (<year>2006</year>): <fpage>217</fpage>&#8211;<lpage>231</lpage>.<pub-id pub-id-type="pmid">16298014</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2005.10.013</pub-id></mixed-citation></ref><ref id="liv70314-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="liv70314-cit-0013"><string-name name-style="western"><given-names>K.</given-names><surname>Wijarnpreecha</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Scribani</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Kim</surname></string-name>, and <string-name name-style="western"><given-names>W. R.</given-names><surname>Kim</surname></string-name>, &#8220;<article-title>The Interaction of Nonalcoholic Fatty Liver Disease and Smoking on Mortality Among Adults in the United States</article-title>,&#8221; <source>Liver International</source><volume>39</volume>, no. <issue>7</issue> (<year>2019</year>): <fpage>1202</fpage>&#8211;<lpage>1206</lpage>.<pub-id pub-id-type="pmid">30697898</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/liv.14058</pub-id></mixed-citation></ref><ref id="liv70314-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="liv70314-cit-0014"><string-name name-style="western"><given-names>P.</given-names><surname>Charatcharoenwitthaya</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Karaketklang</surname></string-name>, and <string-name name-style="western"><given-names>W.</given-names><surname>Aekplakorn</surname></string-name>, &#8220;<article-title>Cigarette Smoking Increased Risk of Overall Mortality in Patients With Non&#8208;Alcoholic Fatty Liver Disease: A Nationwide Population&#8208;Based Cohort Study</article-title>,&#8221; <source>Front Med (Lausanne)</source><volume>7</volume> (<year>2020</year>): <elocation-id>604919</elocation-id>.<pub-id pub-id-type="pmid">33365321</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmed.2020.604919</pub-id><pub-id pub-id-type="pmcid">PMC7750535</pub-id></mixed-citation></ref><ref id="liv70314-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="liv70314-cit-0015"><string-name name-style="western"><given-names>G.</given-names><surname>Corrao</surname></string-name>, <string-name name-style="western"><given-names>A. R.</given-names><surname>Lepore</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Torchio</surname></string-name>, et&#160;al., &#8220;<article-title>The Effect of Drinking Coffee and Smoking Cigarettes on the Risk of Cirrhosis Associated With Alcohol Consumption. A Case&#8208;Control Study. Provincial Group for the Study of Chronic Liver Disease</article-title>,&#8221; <source>European Journal of Epidemiology</source><volume>10</volume>, no. <issue>6</issue> (<year>1994</year>): <fpage>657</fpage>&#8211;<lpage>664</lpage>.<pub-id pub-id-type="pmid">7672043</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF01719277</pub-id></mixed-citation></ref><ref id="liv70314-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="liv70314-cit-0016"><string-name name-style="western"><given-names>R.</given-names><surname>Gaspar</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Rodrigues</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Silva</surname></string-name>, et&#160;al., &#8220;<article-title>Predictive Models of Mortality and Hospital Readmission of Patients With Decompensated Liver Cirrhosis</article-title>,&#8221; <source>Digestive and Liver Disease</source><volume>51</volume>, no. <issue>10</issue> (<year>2019</year>): <fpage>1423</fpage>&#8211;<lpage>1429</lpage>.<pub-id pub-id-type="pmid">31113738</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.dld.2019.03.016</pub-id></mixed-citation></ref><ref id="liv70314-bib-0017"><label>17</label><mixed-citation publication-type="book" id="liv70314-cit-0017"><collab collab-type="authors">International Agency for Research on C</collab>
ancer, <source>IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Polychlorinated Dibenzo&#8208;Para&#8208;Dioxins and Polychlorinated Dibenzofurans</source> (IARC, <year>1997</year>).<pub-id pub-id-type="pmcid">PMC5366851</pub-id><pub-id pub-id-type="pmid">9379504</pub-id></mixed-citation></ref><ref id="liv70314-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="liv70314-cit-0018"><string-name name-style="western"><given-names>S. Y.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>L. Y.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>R. M.</given-names><surname>Lunn</surname></string-name>, et&#160;al., &#8220;<article-title>Polycyclic Aromatic Hydrocarbon&#8208;DNA Adducts in Liver Tissues of Hepatocellular Carcinoma Patients and Controls</article-title>,&#8221; <source>International Journal of Cancer</source><volume>99</volume>, no. <issue>1</issue> (<year>2002</year>): <fpage>14</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="pmid">11948486</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.10291</pub-id></mixed-citation></ref><ref id="liv70314-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="liv70314-cit-0019"><string-name name-style="western"><given-names>Y.</given-names><surname>Geng</surname></string-name>, <string-name name-style="western"><given-names>S. M.</given-names><surname>Savage</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Razani&#8208;Boroujerdi</surname></string-name>, and <string-name name-style="western"><given-names>M. L.</given-names><surname>Sopori</surname></string-name>, &#8220;<article-title>Effects of Nicotine on the Immune Response. II. Chronic Nicotine Treatment Induces T Cell Anergy</article-title>,&#8221; <source>Journal of Immunology</source><volume>156</volume>, no. <issue>7</issue> (<year>1996</year>): <fpage>2384</fpage>&#8211;<lpage>2390</lpage>.<pub-id pub-id-type="pmid">8786295</pub-id></mixed-citation></ref><ref id="liv70314-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="liv70314-cit-0020"><string-name name-style="western"><given-names>M.</given-names><surname>Hoare</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Das</surname></string-name>, and <string-name name-style="western"><given-names>G.</given-names><surname>Alexander</surname></string-name>, &#8220;<article-title>Ageing, Telomeres, Senescence, and Liver Injury</article-title>,&#8221; <source>Journal of Hepatology</source><volume>53</volume>, no. <issue>5</issue> (<year>2010</year>): <fpage>950</fpage>&#8211;<lpage>961</lpage>.<pub-id pub-id-type="pmid">20739078</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2010.06.009</pub-id></mixed-citation></ref><ref id="liv70314-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="liv70314-cit-0021"><string-name name-style="western"><given-names>A.</given-names><surname>Nishida</surname></string-name> and <string-name name-style="western"><given-names>A.</given-names><surname>Andoh</surname></string-name>, &#8220;<article-title>The Role of Inflammation in Cancer: Mechanisms of Tumor Initiation, Progression, and Metastasis</article-title>,&#8221; <source>Cells</source><volume>14</volume>, no. <issue>7</issue> (<year>2025</year>): <elocation-id>488</elocation-id>.<pub-id pub-id-type="pmid">40214442</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells14070488</pub-id><pub-id pub-id-type="pmcid">PMC11987742</pub-id></mixed-citation></ref><ref id="liv70314-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="liv70314-cit-0022"><string-name name-style="western"><given-names>H.</given-names><surname>Bahadar</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Mostafalou</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Abdollahi</surname></string-name>, &#8220;<article-title>Current Understandings and Perspectives on Non&#8208;Cancer Health Effects of Benzene: A Global Concern</article-title>,&#8221; <source>Toxicology and Applied Pharmacology</source><volume>276</volume>, no. <issue>2</issue> (<year>2014</year>): <fpage>83</fpage>&#8211;<lpage>94</lpage>.<pub-id pub-id-type="pmid">24589379</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.taap.2014.02.012</pub-id></mixed-citation></ref><ref id="liv70314-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="liv70314-cit-0023"><string-name name-style="western"><given-names>A.</given-names><surname>Yardley&#8208;Jones</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Anderson</surname></string-name>, and <string-name name-style="western"><given-names>D. V.</given-names><surname>Parke</surname></string-name>, &#8220;<article-title>The Toxicity of Benzene and Its Metabolism and Molecular Pathology in Human Risk Assessment</article-title>,&#8221; <source>British Journal of Industrial Medicine</source><volume>48</volume>, no. <issue>7</issue> (<year>1991</year>): <fpage>437</fpage>&#8211;<lpage>444</lpage>.<pub-id pub-id-type="pmid">1854646</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/oem.48.7.437</pub-id><pub-id pub-id-type="pmcid">PMC1035396</pub-id></mixed-citation></ref><ref id="liv70314-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="liv70314-cit-0024"><string-name name-style="western"><given-names>C. M.</given-names><surname>McHale</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Zhang</surname></string-name>, and <string-name name-style="western"><given-names>M. T.</given-names><surname>Smith</surname></string-name>, &#8220;<article-title>Current Understanding of the Mechanism of Benzene&#8208;Induced Leukemia in Humans: Implications for Risk Assessment</article-title>,&#8221; <source>Carcinogenesis</source><volume>33</volume>, no. <issue>2</issue> (<year>2012</year>): <fpage>240</fpage>&#8211;<lpage>252</lpage>.<pub-id pub-id-type="pmid">22166497</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/carcin/bgr297</pub-id><pub-id pub-id-type="pmcid">PMC3271273</pub-id></mixed-citation></ref><ref id="liv70314-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="liv70314-cit-0025"><string-name name-style="western"><given-names>T.</given-names><surname>Sakamoto</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Higaki</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Hara</surname></string-name>, et&#160;al., &#8220;<article-title>Interaction Between Interleukin&#8208;1&#946; &#8722;31T/C Gene Polymorphism and Drinking and Smoking Habits on the Risk of Hepatocellular Carcinoma Among Japanese</article-title>,&#8221; <source>Cancer Letters</source><volume>271</volume>, no. <issue>1</issue> (<year>2008</year>): <fpage>98</fpage>&#8211;<lpage>104</lpage>.<pub-id pub-id-type="pmid">18603357</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.canlet.2008.05.036</pub-id></mixed-citation></ref><ref id="liv70314-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="liv70314-cit-0026"><string-name name-style="western"><given-names>P.</given-names><surname>Muriel</surname></string-name>, &#8220;<article-title>Role of Free Radicals in Liver Diseases</article-title>,&#8221; <source>Hepatology International</source><volume>3</volume>, no. <issue>4</issue> (<year>2009</year>): <fpage>526</fpage>&#8211;<lpage>536</lpage>.<pub-id pub-id-type="pmid">19941170</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12072-009-9158-6</pub-id><pub-id pub-id-type="pmcid">PMC2790593</pub-id></mixed-citation></ref><ref id="liv70314-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="liv70314-cit-0027"><string-name name-style="western"><given-names>T.</given-names><surname>Reiberger</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Schwabl</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Trauner</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Peck&#8208;Radosavljevic</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Mandorfer</surname></string-name>, &#8220;<article-title>Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy</article-title>,&#8221; <source>Journal of Visualized Experiments</source><volume>160</volume> (<year>2020</year>): <fpage>1</fpage>&#8211;<lpage>16</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3791/58819</pub-id><pub-id pub-id-type="pmid">32628153</pub-id></mixed-citation></ref><ref id="liv70314-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="liv70314-cit-0028"><string-name name-style="western"><given-names>M.</given-names><surname>Mandorfer</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Aigner</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Cejna</surname></string-name>, et&#160;al., &#8220;<article-title>Austrian Consensus on the Diagnosis and Management of Portal Hypertension in Advanced Chronic Liver Disease (Billroth IV)</article-title>,&#8221; <source>Wiener Klinische Wochenschrift</source><volume>135</volume>, no. <issue>Suppl 3</issue> (<year>2023</year>): <fpage>493</fpage>&#8211;<lpage>523</lpage>.<pub-id pub-id-type="pmid">37358642</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00508-023-02229-w</pub-id><pub-id pub-id-type="pmcid">PMC10319704</pub-id></mixed-citation></ref><ref id="liv70314-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="liv70314-cit-0029"><string-name name-style="western"><given-names>R.</given-names><surname>de Franchis</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Bosch</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Garcia&#8208;Tsao</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Reiberger</surname></string-name>, and <string-name name-style="western"><given-names>C.</given-names><surname>Ripoll</surname></string-name>, &#8220;<article-title>Baveno VII &#8208; Renewing Consensus in Portal Hypertension</article-title>,&#8221; <source>Journal of Hepatology</source><volume>76</volume>, no. <issue>4</issue> (<year>2022</year>): <fpage>959</fpage>&#8211;<lpage>974</lpage>.<pub-id pub-id-type="pmid">35120736</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2021.12.022</pub-id><pub-id pub-id-type="pmcid">PMC11090185</pub-id></mixed-citation></ref><ref id="liv70314-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="liv70314-cit-0030"><string-name name-style="western"><given-names>F.</given-names><surname>Qiu</surname></string-name>, <string-name name-style="western"><given-names>C. L.</given-names><surname>Liang</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Liu</surname></string-name>, et&#160;al., &#8220;<article-title>Impacts of Cigarette Smoking on Immune Responsiveness: Up and Down or Upside Down?</article-title>,&#8221; <source>Oncotarget</source><volume>8</volume>, no. <issue>1</issue> (<year>2017</year>): <fpage>268</fpage>&#8211;<lpage>284</lpage>.<pub-id pub-id-type="pmid">27902485</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.13613</pub-id><pub-id pub-id-type="pmcid">PMC5352117</pub-id></mixed-citation></ref><ref id="liv70314-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="liv70314-cit-0031"><string-name name-style="western"><given-names>A.</given-names><surname>Albillos</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Martin&#8208;Mateos</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Van der Merwe</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Wiest</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Jalan</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>&#193;lvarez&#8208;Mon</surname></string-name>, &#8220;<article-title>Cirrhosis&#8208;Associated Immune Dysfunction</article-title>,&#8221; <source>Nature Reviews. Gastroenterology &amp; Hepatology</source><volume>19</volume>, no. <issue>2</issue> (<year>2022</year>): <fpage>112</fpage>&#8211;<lpage>134</lpage>.<pub-id pub-id-type="pmid">34703031</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41575-021-00520-7</pub-id></mixed-citation></ref><ref id="liv70314-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="liv70314-cit-0032"><string-name name-style="western"><given-names>B.</given-names><surname>Simbrunner</surname></string-name>, <string-name name-style="western"><given-names>I. F.</given-names><surname>Villesen</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>K&#246;nigshofer</surname></string-name>, et&#160;al., &#8220;<article-title>Systemic Inflammation Is Linked to Liver Fibrogenesis in Patients With Advanced Chronic Liver Disease</article-title>,&#8221; <source>Liver International</source><volume>42</volume>, no. <issue>11</issue> (<year>2022</year>): <fpage>2501</fpage>&#8211;<lpage>2512</lpage>.<pub-id pub-id-type="pmid">35822301</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/liv.15365</pub-id><pub-id pub-id-type="pmcid">PMC9804351</pub-id></mixed-citation></ref><ref id="liv70314-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="liv70314-cit-0033"><string-name name-style="western"><given-names>D.</given-names><surname>Costa</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Simbrunner</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Jachs</surname></string-name>, et&#160;al., &#8220;<article-title>Systemic Inflammation Increases Across Distinct Stages of Advanced Chronic Liver Disease and Correlates With Decompensation and Mortality</article-title>,&#8221; <source>Journal of Hepatology</source><volume>74</volume>, no. <issue>4</issue> (<year>2021</year>): <fpage>819</fpage>&#8211;<lpage>828</lpage>.<pub-id pub-id-type="pmid">33075344</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2020.10.004</pub-id></mixed-citation></ref><ref id="liv70314-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="liv70314-cit-0034"><string-name name-style="western"><given-names>J.</given-names><surname>Trebicka</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Fernandez</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Papp</surname></string-name>, et&#160;al., &#8220;<article-title>The PREDICT Study Uncovers Three Clinical Courses of Acutely Decompensated Cirrhosis That Have Distinct Pathophysiology</article-title>,&#8221; <source>Journal of Hepatology</source><volume>73</volume>, no. <issue>4</issue> (<year>2020</year>): <fpage>842</fpage>&#8211;<lpage>854</lpage>.<pub-id pub-id-type="pmid">32673741</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2020.06.013</pub-id></mixed-citation></ref><ref id="liv70314-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="liv70314-cit-0035"><string-name name-style="western"><given-names>J.</given-names><surname>Soeda</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Morgan</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>McKee</surname></string-name>, et&#160;al., &#8220;<article-title>Nicotine Induces Fibrogenic Changes in Human Liver via Nicotinic Acetylcholine Receptors Expressed on Hepatic Stellate Cells</article-title>,&#8221; <source>Biochemical and Biophysical Research Communications</source><volume>417</volume>, no. <issue>1</issue> (<year>2012</year>): <fpage>17</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="pmid">22108052</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2011.10.151</pub-id></mixed-citation></ref><ref id="liv70314-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="liv70314-cit-0036"><string-name name-style="western"><given-names>S. R.</given-names><surname>Yang</surname></string-name>, <string-name name-style="western"><given-names>A. S.</given-names><surname>Chida</surname></string-name>, <string-name name-style="western"><given-names>M. R.</given-names><surname>Bauter</surname></string-name>, et&#160;al., &#8220;<article-title>Cigarette Smoke Induces Proinflammatory Cytokine Release by Activation of NF&#8208;kappaB and Posttranslational Modifications of Histone Deacetylase in Macrophages</article-title>,&#8221; <source>American Journal of Physiology. Lung Cellular and Molecular Physiology</source><volume>291</volume>, no. <issue>1</issue> (<year>2006</year>): <fpage>L46</fpage>&#8211;<lpage>L57</lpage>.<pub-id pub-id-type="pmid">16473865</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/ajplung.00241.2005</pub-id></mixed-citation></ref><ref id="liv70314-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="liv70314-cit-0037"><string-name name-style="western"><given-names>C.</given-names><surname>Fischer</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Mazzone</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Jonckx</surname></string-name>, and <string-name name-style="western"><given-names>P.</given-names><surname>Carmeliet</surname></string-name>, &#8220;<article-title>FLT1 and Its Ligands VEGFB and PlGF: Drug Targets for Anti&#8208;Angiogenic Therapy?</article-title>,&#8221; <source>Nature Reviews. Cancer</source><volume>8</volume>, no. <issue>12</issue> (<year>2008</year>): <fpage>942</fpage>&#8211;<lpage>956</lpage>.<pub-id pub-id-type="pmid">19029957</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrc2524</pub-id></mixed-citation></ref><ref id="liv70314-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="liv70314-cit-0038"><string-name name-style="western"><given-names>J.</given-names><surname>Gracia&#8208;Sancho</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Marrone</surname></string-name>, and <string-name name-style="western"><given-names>A.</given-names><surname>Fern&#225;ndez&#8208;Iglesias</surname></string-name>, &#8220;<article-title>Hepatic Microcirculation and Mechanisms of Portal Hypertension</article-title>,&#8221; <source>Nature Reviews. Gastroenterology &amp; Hepatology</source><volume>16</volume>, no. <issue>4</issue> (<year>2019</year>): <fpage>221</fpage>&#8211;<lpage>234</lpage>.<pub-id pub-id-type="pmid">30568278</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41575-018-0097-3</pub-id></mixed-citation></ref><ref id="liv70314-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="liv70314-cit-0039"><string-name name-style="western"><given-names>D.</given-names><surname>Semela</surname></string-name> and <string-name name-style="western"><given-names>J. F.</given-names><surname>Dufour</surname></string-name>, &#8220;<article-title>Angiogenesis and Hepatocellular Carcinoma</article-title>,&#8221; <source>Journal of Hepatology</source><volume>41</volume>, no. <issue>5</issue> (<year>2004</year>): <fpage>864</fpage>&#8211;<lpage>880</lpage>.<pub-id pub-id-type="pmid">15519663</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2004.09.006</pub-id></mixed-citation></ref><ref id="liv70314-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="liv70314-cit-0040"><string-name name-style="western"><given-names>G.</given-names><surname>Semmler</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Lens</surname></string-name>, <string-name name-style="western"><given-names>&#193;.</given-names><surname>Hidalgo</surname></string-name>, et&#160;al., &#8220;<article-title>Incidence and Clinical Significance of Recompensation After HCV Cure</article-title>,&#8221; <source>Clinical Gastroenterology and Hepatology</source> (<year>2025</year>).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cgh.2025.04.026</pub-id><pub-id pub-id-type="pmid">40378989</pub-id></mixed-citation></ref><ref id="liv70314-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="liv70314-cit-0041"><string-name name-style="western"><given-names>F.</given-names><surname>Tovoli</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Stefanini</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Mandrioli</surname></string-name>, et&#160;al., &#8220;<article-title>Exploring Occupational Toxicant Exposures in Patients With Metabolic Dysfunction&#8208;Associated Steatotic Liver Disease: A Prospective Pilot Study</article-title>,&#8221; <source>Digestive and Liver Disease</source><volume>56</volume>, no. <issue>4</issue> (<year>2024</year>): <fpage>571</fpage>&#8211;<lpage>578</lpage>.<pub-id pub-id-type="pmid">38151451</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.dld.2023.12.007</pub-id></mixed-citation></ref><ref id="liv70314-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="liv70314-cit-0042"><string-name name-style="western"><given-names>H. B.</given-names><surname>El&#8208;Serag</surname></string-name>, &#8220;<article-title>Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma</article-title>,&#8221; <source>Gastroenterology</source><volume>142</volume>, no. <issue>6</issue> (<year>2012</year>): <fpage>1264</fpage>&#8211;<lpage>1273.e1</lpage>.<pub-id pub-id-type="pmid">22537432</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2011.12.061</pub-id><pub-id pub-id-type="pmcid">PMC3338949</pub-id></mixed-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>